<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9268086</PMID>
        <DateCreated>
            <Year>1997</Year>
            <Month>10</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1997</Year>
            <Month>10</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0021-5198</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>74</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1997</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Japanese journal of pharmacology</Title>
                <ISOAbbreviation>Jpn. J. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of long-term administration of berberine on scopolamine-induced amnesia in rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>261-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The effect of berberine (BER) on scopolamine (SCOP)-induced amnesia was investigated in a step-through passive avoidance task in rats. It was observed that BER at the doses of 0.1 and 0.5 g/kg after 7-day or 14-day administration significantly improved SCOP-induced amnesia. The anti-amnesic effect of BER after 14-day administration on the SCOP-induced amnesia was significantly augmented by physostigmine or neostigmine, and completely reversed by scopolamine N-methylbromide. These results suggest that the antiamnesic effect of BER after 14-day administration may be related to the increase in the peripheral and central cholinergic neuronal system activity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>W H</ForeName>
                    <Initials>WH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Chinese Pharmaceutical Sciences, Chiba Medical College, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsieh</LastName>
                    <ForeName>M T</ForeName>
                    <Initials>MT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>C R</ForeName>
                    <Initials>CR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>JAPAN</Country>
            <MedlineTA>Jpn J Pharmacol</MedlineTA>
            <NlmUniqueID>2983305R</NlmUniqueID>
            <ISSNLinking>0021-5198</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018727">Muscarinic Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0I8Y3P32UF</RegistryNumber>
                <NameOfSubstance UI="D001599">Berberine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>451IFR0GXB</RegistryNumber>
                <NameOfSubstance UI="D012601">Scopolamine Hydrobromide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000647">Amnesia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001599">Berberine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002800">Cholinesterase Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004347">Drug Interactions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007858">Learning</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018727">Muscarinic Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012601">Scopolamine Hydrobromide</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1997</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1997</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1997</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9268086</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1210484</PMID>
        <DateCreated>
            <Year>1976</Year>
            <Month>04</Month>
            <Day>02</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1976</Year>
            <Month>04</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0300-967X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>179</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>1975</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Zeitschrift f√ºr Geburtshilfe und Perinatologie</Title>
                <ISOAbbreviation>Z Geburtshilfe Perinatol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Perinatal deaths associated with paracervical anesthesia (author's transl)].</ArticleTitle>
            <Pagination>
                <MedlinePgn>396-400</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Two infants' death associated with paracervical anesthesia are reported. In both cases a severe fetal bradycardia which developed 5 and 10 minutes, respectively, after paracervical injection of 10 ml of 0.5% Bupivacain, was the reason for Caesarean section. The clinical signs of the infants were similar: low Apgar score, primary apnea, grey colour, flaccidity, no reactions; after a few hours, however, general muscular hypertonus, and repeated attacks of tonic seizures. Accidental injection of Bupivacain into the fetus cannot be excluded in both cases. -- The fetal risks through paracervical anesthesia are being reviewed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Eisenberg</LastName>
                </Author>
            </AuthorList>
            <Language>ger</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Kindliche Todesf√§lle im Zusammenhang mit Parazervikalan√§sthesie</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>GERMANY, WEST</Country>
            <MedlineTA>Z Geburtshilfe Perinatol</MedlineTA>
            <NlmUniqueID>0326205</NlmUniqueID>
            <ISSNLinking>0300-967X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000777">Anesthetics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000779">Anesthetics, Local</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>B6E06QE59J</RegistryNumber>
                <NameOfSubstance UI="D008619">Mepivacaine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Y8335394RO</RegistryNumber>
                <NameOfSubstance UI="D002045">Bupivacaine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000773">Anesthesia, Obstetrical</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000777">Anesthetics</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000779">Anesthetics, Local</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001034">Apgar Score</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001919">Bradycardia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002045">Bupivacaine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000506">poisoning</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002584">Cervix Uteri</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002585">Cesarean Section</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007226">Infant Mortality</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007232">Infant, Newborn, Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008431">Maternal-Fetal Exchange</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008619">Mepivacaine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000506">poisoning</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1975</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1975</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1975</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1210484</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12111688</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>07</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2002</Year>
            <Month>09</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2007</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0271-3586</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>42</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of industrial medicine</Title>
                <ISOAbbreviation>Am. J. Ind. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Association between asbestos exposure, cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk.</ArticleTitle>
            <Pagination>
                <MedlinePgn>29-37</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">As observed in tobacco-associated carcinogenesis, genetic factors such as the polymorphic metabolic/oxidative enzyme myeloperoxidase (MPO) could modulate individual susceptibility to asbestos-associated carcinogenesis.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">RFLP-PCR analysis identified the MPO genotypes in 375 Caucasian lung cancer cases and 378 matched controls. An epidemiological interview elicited detailed information regarding smoking history and occupational history and exposures.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Asbestos exposure was associated with a significantly elevated risk estimate (OR = 1.45; 95% CI 1.04-2.02). On stratified analysis, we found the MPO genotypes modified the effect of asbestos exposure on lung cancer risk. Specifically, G/G carriers who were exposed to asbestos had an odds ratio (OR) of 1.72 (95% CI; 1.09-2.66), while A-allele carriers (G/A + A/A) exposed to asbestos exhibited a reduced OR of 0.89 (95% CI; 0.56-1.44). The OR was further reduced to 0.73 (0.49-1.06) for A-allele carriers not exposed to asbestos. A similar trend was observed for the joint effects between the MPO genotypes and pack-years smoking. Next, all three risk factors (MPO genotypes, asbestos exposure, and smoking) were analyzed simultaneously for joint effects. Heavy smokers with the G/G genotype and a history of asbestos exposure demonstrated a statistically significant elevated risk estimate (OR = 2.19; 95% CI 1.16-4.11), while the A-allele carriers with the same exposure profile were at a lower risk for lung cancer (OR = 1.18; 95% CI 0.58-2.38). The A-allele genotypes demonstrated similar protective effects for the other three exposure profiles.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">For a similar level of exposure to established carcinogens, individuals with the MPO A-allele genotypes appear to have a reduced risk of lung cancer.</AbstractText>
                <CopyrightInformation>Copyright 2002 Wiley-Liss, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Schabath</LastName>
                    <ForeName>Matthew B</ForeName>
                    <Initials>MB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Holcombe Blvd, Houston, Texas 77303, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spitz</LastName>
                    <ForeName>Margaret R</ForeName>
                    <Initials>MR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Delclos</LastName>
                    <ForeName>George L</ForeName>
                    <Initials>GL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gunn</LastName>
                    <ForeName>Gary B</ForeName>
                    <Initials>GB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Whitehead</LastName>
                    <ForeName>Lawrence W</ForeName>
                    <Initials>LW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Xifeng</ForeName>
                    <Initials>X</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R25 CA57730</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Ind Med</MedlineTA>
            <NlmUniqueID>8101110</NlmUniqueID>
            <ISSNLinking>0271-3586</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>1332-21-4</RegistryNumber>
                <NameOfSubstance UI="D001194">Asbestos</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.11.1.7</RegistryNumber>
                <NameOfSubstance UI="D009195">Peroxidase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000483">Alleles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001194">Asbestos</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004198">Disease Susceptibility</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D005838">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016273">Occupational Exposure</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009195">Peroxidase</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011110">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012306">Risk</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012907">Smoking</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>7</Month>
                <Day>12</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>9</Month>
                <Day>13</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>7</Month>
                <Day>12</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12111688</ArticleId>
            <ArticleId IdType="doi">10.1002/ajim.10084</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18176751</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>01</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>06</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0001-5555</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>88</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2008</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Acta dermato-venereologica</Title>
                <ISOAbbreviation>Acta Derm. Venereol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Conradi-H√ºnermann-Happle syndrome (X-linked dominant chondrodysplasia punctata) confirmed by plasma sterol and mutation analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>47-51</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2340/00015555-0337</ELocationID>
            <Abstract>
                <AbstractText>Conradi-H√ºnermann-Happle syndrome, or X-linked dominant chondrodysplasia punctata, is a rare genetic disorder characterized by skeletal dysplasia, stippled epiphyses, cataracts, transient ichthyosis and atrophic residua in a mosaic pattern. Mutations in the gene encoding the emopamil-binding protein have been identified as an underlying cause. A 5-year-old girl presented for evaluation of ill-defined patches of cicatricial alopecia. In addition, subtle follicular atrophoderma, esotropia, craniofacial asymmetry and short stature were noted. Her history revealed widespread scaly erythema and eye surgery for congenital cataract in the first months of life. Diagnosis of Conradi-H√ºnermann-Happle syndrome was confirmed by plasma sterol analysis showing markedly elevated levels of 8(9)-cholestenol and 8-dehydrocholesterol and by detection of a missense mutation (c.307G&gt;A; p.E103K) in the emopamil-binding protein gene. We suggest that plasma sterol analysis is a reliable method of establishing the diagnosis of Conradi-H√ºnermann-Happle syndrome, even in patients with less striking phenotypical changes beyond infancy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kolb-M√§urer</LastName>
                    <ForeName>Annette</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Dermatology, University of W√ºrzburg, Josef-Schneider-Strasse 2, W√ºrzburg, Germany. kolb_a@klinik.uni-wuerzburg.de</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grzeschik</LastName>
                    <ForeName>Karl-Heinz</ForeName>
                    <Initials>KH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haas</LastName>
                    <ForeName>Dorothea</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Br√∂cker</LastName>
                    <ForeName>Eva-Bettina</ForeName>
                    <Initials>EB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamm</LastName>
                    <ForeName>Henning</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Sweden</Country>
            <MedlineTA>Acta Derm Venereol</MedlineTA>
            <NlmUniqueID>0370310</NlmUniqueID>
            <ISSNLinking>0001-5555</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002775">Cholestadienols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>70741-38-7</RegistryNumber>
                <NameOfSubstance UI="C026359">cholesta-5,8-dien-3 beta-ol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>97C5T2UQ7J</RegistryNumber>
                <NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 5.3.3.-</RegistryNumber>
                <NameOfSubstance UI="D013251">Steroid Isomerases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 5.3.3.5</RegistryNumber>
                <NameOfSubstance UI="C090445">EBP protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>L3GY707BLC</RegistryNumber>
                <NameOfSubstance UI="C056855">zymostenol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000505">Alopecia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002386">Cataract</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002775">Cholestadienols</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002784">Cholesterol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002806">Chondrodysplasia Punctata</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019465">Craniofacial Abnormalities</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004252">DNA Mutational Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005123">Eye</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005799">Genes, Dominant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017496">Hypopigmentation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020125">Mutation, Missense</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012867">Skin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013251">Steroid Isomerases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>1</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>6</Month>
                <Day>3</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>1</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.2340/00015555-0337</ArticleId>
            <ArticleId IdType="pubmed">18176751</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2388211</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>09</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>09</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0315-162X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>17</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>1990</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of rheumatology</Title>
                <ISOAbbreviation>J. Rheumatol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hepatic fibrosis with the use of methotrexate for juvenile rheumatoid arthritis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>846-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Methotrexate (MTX) is currently under study for use in juvenile rheumatoid arthritis. One complication of MTX is hepatotoxicity. Although liver function tests may be abnormal with its use, in this setting they do not correlate well with the development of hepatic fibrosis. Periodic liver biopsy is required to monitor for the hepatotoxic changes secondary to MTX. We describe and discuss the case of a 17-year-old woman who developed evidence of hepatic fibrosis after 3 years of MTX therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Keim</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, University of Michigan Hospitals, Ann Arbor.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ragsdale</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heidelberger</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sullivan</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>CANADA</Country>
            <MedlineTA>J Rheumatol</MedlineTA>
            <NlmUniqueID>7501984</NlmUniqueID>
            <ISSNLinking>0315-162X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>YL5FZ2Y5U1</RegistryNumber>
                <NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001171">Arthritis, Juvenile</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001706">Biopsy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008103">Liver Cirrhosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008727">Methotrexate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1990</Year>
                <Month>6</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1990</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1990</Year>
                <Month>6</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2388211</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15732116</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>03</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>04</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2008</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0364-5134</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>57</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of neurology</Title>
                <ISOAbbreviation>Ann. Neurol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Vascular endothelial growth factor gene variability is associated with increased risk for AD.</ArticleTitle>
            <Pagination>
                <MedlinePgn>373-80</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Converging evidence points to a pivotal role of vascular endothelial growth factor (VEGF) in neuronal protection and a lack of its activity in neurodegenerative disorders. To investigate this possible association, we screened the VEGF gene promoter for various well-known single-nucleotide polymorphisms in a series of 249 consecutively recruited Italian patients with sporadic Alzheimer's disease (AD). Genetic analysis indicated different distributions of two single-nucleotide polymorphisms in the AD population compared with healthy control subjects. In particular, the frequencies of -2578A/A and -1198C/T genotypes were significantly greater in AD patients than in control subjects (23.7 vs 14.7% and 2.8 vs 0%, respectively). The -2578A/A genotype was associated with an increased risk for disease, independently of apolipoprotein E genotype. The risk was significantly increased with respect to various VEGF genotype combinations. In contrast, no difference in serum VEGF levels was detected comparing 96 patients and 49 control subjects. These findings suggest that polymorphisms within the promoter region of the VEGF gene confer greater risk for AD, probably by reducing its neuroprotective effect, and confirm the biological role of VEGF in neurodegenerative processes.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Del Bo</LastName>
                    <ForeName>Roberto</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurological Sciences, Dino Ferrari Centre and Centre of Excellence on Neurodegenerative Diseases, University of Milan, I.R.C.C.S. Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy. roberto.delbo@unimi.it</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scarlato</LastName>
                    <ForeName>Marina</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghezzi</LastName>
                    <ForeName>Serena</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martinelli Boneschi</LastName>
                    <ForeName>Filippo</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fenoglio</LastName>
                    <ForeName>Chiara</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Galbiati</LastName>
                    <ForeName>Sara</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Virgilio</LastName>
                    <ForeName>Roberta</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Galimberti</LastName>
                    <ForeName>Daniela</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Galimberti</LastName>
                    <ForeName>Gloria</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Crimi</LastName>
                    <ForeName>Marco</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferrarese</LastName>
                    <ForeName>Carlo</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scarpini</LastName>
                    <ForeName>Elio</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bresolin</LastName>
                    <ForeName>Nereo</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Comi</LastName>
                    <ForeName>Giacomo P</ForeName>
                    <Initials>GP</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Neurol</MedlineTA>
            <NlmUniqueID>7707449</NlmUniqueID>
            <ISSNLinking>0364-5134</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D042442">Vascular Endothelial Growth Factors</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Ann Neurol. 2005 Sep;58(3):488; author reply 488-9</RefSource>
                <PMID Version="1">16130099</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000544">Alzheimer Disease</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016009">Chi-Square Distribution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016001">Confidence Intervals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005838">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008967">Molecular Biology</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D012306">Risk</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D042442">Vascular Endothelial Growth Factors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>2</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>4</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>2</Month>
                <Day>26</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20390</ArticleId>
            <ArticleId IdType="pubmed">15732116</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23872636</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>01</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>DYX1C1 is required for axonemal dynein assembly and ciliary motility.</ArticleTitle>
            <Pagination>
                <MedlinePgn>995-1003</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2707</ELocationID>
            <Abstract>
                <AbstractText>DYX1C1 has been associated with dyslexia and neuronal migration in the developing neocortex. Unexpectedly, we found that deleting exons 2-4 of Dyx1c1 in mice caused a phenotype resembling primary ciliary dyskinesia (PCD), a disorder characterized by chronic airway disease, laterality defects and male infertility. This phenotype was confirmed independently in mice with a Dyx1c1 c.T2A start-codon mutation recovered from an N-ethyl-N-nitrosourea (ENU) mutagenesis screen. Morpholinos targeting dyx1c1 in zebrafish also caused laterality and ciliary motility defects. In humans, we identified recessive loss-of-function DYX1C1 mutations in 12 individuals with PCD. Ultrastructural and immunofluorescence analyses of DYX1C1-mutant motile cilia in mice and humans showed disruptions of outer and inner dynein arms (ODAs and IDAs, respectively). DYX1C1 localizes to the cytoplasm of respiratory epithelial cells, its interactome is enriched for molecular chaperones, and it interacts with the cytoplasmic ODA and IDA assembly factor DNAAF2 (KTU). Thus, we propose that DYX1C1 is a newly identified dynein axonemal assembly factor (DNAAF4).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tarkar</LastName>
                    <ForeName>Aarti</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology and Neurobiology, University of Connecticut, Storrs, Connecticut, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loges</LastName>
                    <ForeName>Niki T</ForeName>
                    <Initials>NT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Slagle</LastName>
                    <ForeName>Christopher E</ForeName>
                    <Initials>CE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Francis</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dougherty</LastName>
                    <ForeName>Gerard W</ForeName>
                    <Initials>GW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tamayo</LastName>
                    <ForeName>Joel V</ForeName>
                    <Initials>JV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shook</LastName>
                    <ForeName>Brett</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cantino</LastName>
                    <ForeName>Marie</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schwartz</LastName>
                    <ForeName>Daniel</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jahnke</LastName>
                    <ForeName>Charlotte</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olbrich</LastName>
                    <ForeName>Heike</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Werner</LastName>
                    <ForeName>Claudius</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Raidt</LastName>
                    <ForeName>Johanna</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pennekamp</LastName>
                    <ForeName>Petra</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abouhamed</LastName>
                    <ForeName>Marouan</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hjeij</LastName>
                    <ForeName>Rim</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>K√∂hler</LastName>
                    <ForeName>Gabriele</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Griese</LastName>
                    <ForeName>Matthias</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>You</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lemke</LastName>
                    <ForeName>Kristi</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klena</LastName>
                    <ForeName>Nikolas</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Xiaoqin</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gabriel</LastName>
                    <ForeName>George</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tobita</LastName>
                    <ForeName>Kimimasa</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jaspers</LastName>
                    <ForeName>Martine</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morgan</LastName>
                    <ForeName>Lucy C</ForeName>
                    <Initials>LC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shapiro</LastName>
                    <ForeName>Adam J</ForeName>
                    <Initials>AJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Letteboer</LastName>
                    <ForeName>Stef J F</ForeName>
                    <Initials>SJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mans</LastName>
                    <ForeName>Dorus A</ForeName>
                    <Initials>DA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carson</LastName>
                    <ForeName>Johnny L</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leigh</LastName>
                    <ForeName>Margaret W</ForeName>
                    <Initials>MW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wolf</LastName>
                    <ForeName>Whitney E</ForeName>
                    <Initials>WE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Serafine</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lucas</LastName>
                    <ForeName>Jane S</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Onoufriadis</LastName>
                    <ForeName>Alexandros</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Plagnol</LastName>
                    <ForeName>Vincent</ForeName>
                    <Initials>V</Initials>
                    <Identifier Source="ORCID">0000000255979215</Identifier>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schmidts</LastName>
                    <ForeName>Miriam</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boldt</LastName>
                    <ForeName>Karsten</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>UK10K</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roepman</LastName>
                    <ForeName>Ronald</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zariwala</LastName>
                    <ForeName>Maimoona A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lo</LastName>
                    <ForeName>Cecilia W</ForeName>
                    <Initials>CW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mitchison</LastName>
                    <ForeName>Hannah M</ForeName>
                    <Initials>HM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Knowles</LastName>
                    <ForeName>Michael R</ForeName>
                    <Initials>MR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burdine</LastName>
                    <ForeName>Rebecca D</ForeName>
                    <Initials>RD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loturco</LastName>
                    <ForeName>Joseph J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Omran</LastName>
                    <ForeName>Heymut</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>2 R01HD048584</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>5 R01HL071798</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>5 U54 HL096458-06</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>NF-SI-0510-10268</GrantID>
                    <Agency>Department of Health</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>P01 HD020806</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01 HD057853</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01 HD057853</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HD048584</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HD055655</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HD055655</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL071798</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 MH056524</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 MH056524</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 CA009156</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 HL098180</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01HL098180</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UL1 TR000083</GrantID>
                    <Acronym>TR</Acronym>
                    <Agency>NCATS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>WT091310</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>07</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C584544">DYX1C1 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.4.2</RegistryNumber>
                <NameOfSubstance UI="D056444">Axonemal Dyneins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Genet. 2006 Sep;120(2):171-8</RefSource>
                <PMID Version="1">16783569</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Trends Cardiovasc Med. 2004 Feb;14(2):43-9</RefSource>
                <PMID Version="1">15030788</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Physiol. 2007;69:423-50</RefSource>
                <PMID Version="1">17059358</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3336-41</RefSource>
                <PMID Version="1">17360648</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2007 Jun 5;115(22):2814-21</RefSource>
                <PMID Version="1">17515466</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Brain Behav. 2007 Oct;6(7):640-6</RefSource>
                <PMID Version="1">17309662</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cereb Cortex. 2007 Nov;17(11):2562-72</RefSource>
                <PMID Version="1">17218481</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Mol Cell Biol. 2007 Nov;8(11):880-93</RefSource>
                <PMID Version="1">17955020</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2007 Dec;117(12):3742-52</RefSource>
                <PMID Version="1">18037990</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mutat. 2008 Feb;29(2):289-98</RefSource>
                <PMID Version="1">18022865</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell. 1999 Oct;4(4):459-68</RefSource>
                <PMID Version="1">10549278</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 1999 Dec;65(6):1508-19</RefSource>
                <PMID Version="1">10577904</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Cell Mol Biol. 2000 Dec;23(6):734-41</RefSource>
                <PMID Version="1">11104725</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2002 Feb;30(2):143-4</RefSource>
                <PMID Version="1">11788826</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10282-6</RefSource>
                <PMID Version="1">12142464</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2008 Dec 4;456(7222):611-6</RefSource>
                <PMID Version="1">19052621</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2008 Nov;83(5):547-58</RefSource>
                <PMID Version="1">18950741</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2009 Feb;84(2):197-209</RefSource>
                <PMID Version="1">19200523</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2009 Aug 1;18(15):2802-12</RefSource>
                <PMID Version="1">19423554</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cancer Res Clin Oncol. 2009 Sep;135(9):1265-76</RefSource>
                <PMID Version="1">19277710</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2009 Dec;85(6):883-9</RefSource>
                <PMID Version="1">19944400</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2009 Dec;85(6):890-6</RefSource>
                <PMID Version="1">19944405</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2010;5(5):e10704</RefSource>
                <PMID Version="1">20502701</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Biol. 1981 Jun;84(2):372-85</RefSource>
                <PMID Version="1">20737876</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Cells. 2004 Jun;9(6):533-48</RefSource>
                <PMID Version="1">15189447</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2004 Sep 15;13(18):2133-41</RefSource>
                <PMID Version="1">15269178</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Methods Enzymol. 1993;225:361-73</RefSource>
                <PMID Version="1">8231863</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14895-900</RefSource>
                <PMID Version="1">8962152</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 1998 Mar;139(3):1440-9</RefSource>
                <PMID Version="1">9492081</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Genes Evol. 1998 Jul;208(5):245-58</RefSource>
                <PMID Version="1">9683740</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Biol. 1999 Oct 1;214(1):23-37</RefSource>
                <PMID Version="1">10491254</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Genet. 2004 Nov;41(11):853-7</RefSource>
                <PMID Version="1">15520411</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Psychiatry. 2004 Dec;9(12):1111-21</RefSource>
                <PMID Version="1">15249932</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Hum Genet. 2005 Apr;13(4):491-9</RefSource>
                <PMID Version="1">15702132</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2005 Jun 15;171(12):1343-9</RefSource>
                <PMID Version="1">15750039</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Genet. 2005 Oct;118(1):87-90</RefSource>
                <PMID Version="1">16133186</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Res. 2006 Mar;59(3):418-22</RefSource>
                <PMID Version="1">16492982</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Reprod Dev. 2006 Jun;73(6):784-94</RefSource>
                <PMID Version="1">16496424</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Genet. 2006 Apr;43(4):326-33</RefSource>
                <PMID Version="1">16055928</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Psychiatry. 2010 Dec;15(12):1190-6</RefSource>
                <PMID Version="1">19901951</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Jan;43(1):72-8</RefSource>
                <PMID Version="1">21131972</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Jan;43(1):79-84</RefSource>
                <PMID Version="1">21131974</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2011 May 13;88(5):599-607</RefSource>
                <PMID Version="1">21496787</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Vet Pathol. 2012 Jan;49(1):166-81</RefSource>
                <PMID Version="1">21746835</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2012;7(3):e33667</RefSource>
                <PMID Version="1">22448264</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Apr;44(4):381-9, S1-2</RefSource>
                <PMID Version="1">22387996</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Thorax. 2012 May;67(5):433-41</RefSource>
                <PMID Version="1">22184204</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2012;7(4):e35618</RefSource>
                <PMID Version="1">22558177</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Jun;44(6):714-9</RefSource>
                <PMID Version="1">22581229</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2012 Oct 5;91(4):672-84</RefSource>
                <PMID Version="1">23022101</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2012 Nov 1;28(21):2747-54</RefSource>
                <PMID Version="1">22942019</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2012 Nov 2;91(5):958-64</RefSource>
                <PMID Version="1">23122589</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2012;7(12):e52166</RefSource>
                <PMID Version="1">23300604</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Psychiatry. 2013 Mar 15;73(6):583-90</RefSource>
                <PMID Version="1">23036959</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11553-8</RefSource>
                <PMID Version="1">12954984</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Microsc. 2003 Aug;211(Pt 2):103-11</RefSource>
                <PMID Version="1">12887704</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2013;8(5):e63123</RefSource>
                <PMID Version="1">23650548</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuroscience. 2006 Dec 1;143(2):515-22</RefSource>
                <PMID Version="1">16989952</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056444">Axonemal Dyneins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002923">Cilia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004805">Ependyma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D023061">Gene Order</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018390">Gene Targeting</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D042541">Intracellular Space</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007619">Kartagener Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009419">Nerve Tissue Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020545">Respiratory Mucosa</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015027">Zebrafish</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS520013</OtherID>
        <OtherID Source="NLM">PMC4000444</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2707</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2707</ArticleId>
            <ArticleId IdType="pubmed">23872636</ArticleId>
            <ArticleId IdType="pmc">PMC4000444</ArticleId>
            <ArticleId IdType="mid">NIHMS520013</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17984431</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>11</Month>
            <Day>06</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>03</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0896-8608</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>27</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <MedlineDate>2007 Nov-Dec</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis</Title>
                <ISOAbbreviation>Perit Dial Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Intraperitoneal calcitriol in infants on peritoneal dialysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>681-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Calcitriol has long been used as the main therapy in renal osteodystrophy, but the efficacy of the oral route is not always as high as expected.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To asses the safety and efficacy of intraperitoneal calcitriol in infants undergoing peritoneal dialysis (PD).</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">PD patients on oral calcitriol therapy, with serum parathyroid hormone (PTH) &gt;1000 pg/mL during the previous 3 months of treatment, were switched to intraperitoneal calcitriol therapy, 1 microg twice per week. Dose was increased to 1 microg three times per week if PTH remained &gt;1000 pg/mL, and was later readjusted. Target PTH was 200-300 pg/mL according DOQI guidelines.</AbstractText>
                <AbstractText Label="STATISTICS" NlmCategory="METHODS">All results are expressed as mean +/- SE. The Wilcoxon signed rank test was used to evaluate differences in measurements for each pair of values. The confidence interval for differences between population medians was 96.9%. A p value less than 0.05 was considered significant.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Six male children, mean age 17 +/- 3.86 months, completed a 12-month follow-up. Mean pretreatment PTH was 1654 +/- 209 pg/mL. Mean PTH at months 0, 3, 6, 9, and 12 was 1448 +/- 439*, 1277 +/- 723, 910 +/- 704, 582 +/- 282*, and 465 +/- 224* pg/mL, respectively (*p &lt; 0.05). Twelve hypercalcemic and 10 hyperphosphatemic episodes were successfully treated.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Infants on PD who fail to respond to oral calcitriol therapy can be safely treated with intraperitoneal administration of active vitamin D.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cano</LastName>
                    <ForeName>Francisco J</ForeName>
                    <Initials>FJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pediatric Nephrology, Department of Pediatrics, Luis Calvo Mackenna Children's Hospital, University of Chile, Santiago, Chile. fcano@med.uchile.cl</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Azocar</LastName>
                    <ForeName>Marta A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guerrero</LastName>
                    <ForeName>Jose Luis</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Delucchi</LastName>
                    <ForeName>Maria A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lillo</LastName>
                    <ForeName>Ana Maria</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Emilfork</LastName>
                    <ForeName>Marcos</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rodr√≠guez</LastName>
                    <ForeName>Eugenio E</ForeName>
                    <Initials>EE</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Canada</Country>
            <MedlineTA>Perit Dial Int</MedlineTA>
            <NlmUniqueID>8904033</NlmUniqueID>
            <ISSNLinking>0896-8608</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010281">Parathyroid Hormone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>27YLU75U4W</RegistryNumber>
                <NameOfSubstance UI="D010758">Phosphorus</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.3.1</RegistryNumber>
                <NameOfSubstance UI="D000469">Alkaline Phosphatase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>FXC9231JVH</RegistryNumber>
                <NameOfSubstance UI="D002117">Calcitriol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>SY7Q814VUP</RegistryNumber>
                <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Perit Dial Int. 2007 Nov-Dec;27(6):651-3</RefSource>
                <PMID Version="1">17984426</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000469">Alkaline Phosphatase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050071">Bone Density Conservation Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002117">Calcitriol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002118">Calcium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006934">Hypercalcemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006962">Hyperparathyroidism, Secondary</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D054559">Hyperphosphatemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007274">Injections, Intraperitoneal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007676">Kidney Failure, Chronic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010281">Parathyroid Hormone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D010530">Peritoneal Dialysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010758">Phosphorus</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018709">Statistics, Nonparametric</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>11</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>3</Month>
                <Day>28</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>11</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">27/6/681</ArticleId>
            <ArticleId IdType="pubmed">17984431</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9621905</PMID>
        <DateCreated>
            <Year>1998</Year>
            <Month>08</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1998</Year>
            <Month>08</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0021-9924</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>31</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <MedlineDate>1998 May-Jun</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of communication disorders</Title>
                <ISOAbbreviation>J Commun Disord</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Comparative study of the phonology of preschool children prenatally exposed to cocaine and multiple drugs and non-exposed children.</ArticleTitle>
            <Pagination>
                <MedlinePgn>231-43; quiz 243-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Cocaine and multiple drug abuse among young adults has spawned research interest in fetal exposure and the sequela of that exposure during the formative developmental years. Previous study of the language development of exposed children has not specifically addressed phonological acquisition. In the present study, the speech of 25 children prenatally exposed to cocaine and multiple drugs was analyzed and compared to that of 25 children who were not prenatally exposed to determine if differences were evident in their phonological patterns. The children ranged in age from 22 months to 51 months. The number and type of phonological processes produced, number of utterances needed to produce a 50-word sample, number of unintelligible words produced, and Home Observation for Measurement of the Environment (HOME) scores were recorded and analyzed. The use of cocaine and multiple drugs during pregnancy was associated with an increase in the use of phonological processes.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Madison</LastName>
                    <ForeName>C L</ForeName>
                    <Initials>CL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Washington State University, Spokane 99204-0399, USA. madisonc@wsu.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johnson</LastName>
                    <ForeName>J M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seikel</LastName>
                    <ForeName>J A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arnold</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schultheis</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Commun Disord</MedlineTA>
            <NlmUniqueID>0260316</NlmUniqueID>
            <ISSNLinking>0021-9924</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I5Y540LHVR</RegistryNumber>
                <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001184">Articulation Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007805">Language Development Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011297">Prenatal Exposure Delayed Effects</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011619">Psychotropic Drugs</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013065">Speech Intelligibility</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019966">Substance-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1998</Year>
                <Month>6</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1998</Year>
                <Month>6</Month>
                <Day>11</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1998</Year>
                <Month>6</Month>
                <Day>11</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9621905</ArticleId>
            <ArticleId IdType="pii">S0021-9924(97)00091-9</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23872634</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>02</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>45</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1044-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2712</ELocationID>
            <Abstract>
                <AbstractText>Brugada syndrome is a rare cardiac arrhythmia disorder, causally related to SCN5A mutations in around 20% of cases. Through a genome-wide association study of 312 individuals with Brugada syndrome and 1,115 controls, we detected 2 significant association signals at the SCN10A locus (rs10428132) and near the HEY2 gene (rs9388451). Independent replication confirmed both signals (meta-analyses: rs10428132, P = 1.0 √ó 10(-68); rs9388451, P = 5.1 √ó 10(-17)) and identified one additional signal in SCN5A (at 3p21; rs11708996, P = 1.0 √ó 10(-14)). The cumulative effect of the three loci on disease susceptibility was unexpectedly large (Ptrend = 6.1 √ó 10(-81)). The association signals at SCN5A-SCN10A demonstrate that genetic polymorphisms modulating cardiac conduction can also influence susceptibility to cardiac arrhythmia. The implication of association with HEY2, supported by new evidence that Hey2 regulates cardiac electrical activity, shows that Brugada syndrome may originate from altered transcriptional programming during cardiac development. Altogether, our findings indicate that common genetic variation can have a strong impact on the predisposition to rare diseases.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bezzina</LastName>
                    <ForeName>Connie R</ForeName>
                    <Initials>CR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical and Experimental Cardiology, Heart Failure Research Center, Academic Medical Center, Amsterdam, The Netherlands. c.r.bezzina@amc.uva.nl</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barc</LastName>
                    <ForeName>Julien</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mizusawa</LastName>
                    <ForeName>Yuka</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Remme</LastName>
                    <ForeName>Carol Ann</ForeName>
                    <Initials>CA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gourraud</LastName>
                    <ForeName>Jean-Baptiste</ForeName>
                    <Initials>JB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Simonet</LastName>
                    <ForeName>Floriane</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Verkerk</LastName>
                    <ForeName>Arie O</ForeName>
                    <Initials>AO</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schwartz</LastName>
                    <ForeName>Peter J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Crotti</LastName>
                    <ForeName>Lia</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dagradi</LastName>
                    <ForeName>Federica</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guicheney</LastName>
                    <ForeName>Pascale</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fressart</LastName>
                    <ForeName>V√©ronique</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leenhardt</LastName>
                    <ForeName>Antoine</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Antzelevitch</LastName>
                    <ForeName>Charles</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bartkowiak</LastName>
                    <ForeName>Susan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Borggrefe</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schimpf</LastName>
                    <ForeName>Rainer</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schulze-Bahr</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zumhagen</LastName>
                    <ForeName>Sven</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Behr</LastName>
                    <ForeName>Elijah R</ForeName>
                    <Initials>ER</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bastiaenen</LastName>
                    <ForeName>Rachel</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tfelt-Hansen</LastName>
                    <ForeName>Jacob</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olesen</LastName>
                    <ForeName>Morten Salling</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>K√§√§b</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beckmann</LastName>
                    <ForeName>Britt M</ForeName>
                    <Initials>BM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weeke</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Watanabe</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Endo</LastName>
                    <ForeName>Naoto</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Minamino</LastName>
                    <ForeName>Tohru</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Horie</LastName>
                    <ForeName>Minoru</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ohno</LastName>
                    <ForeName>Seiko</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hasegawa</LastName>
                    <ForeName>Kanae</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Makita</LastName>
                    <ForeName>Naomasa</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nogami</LastName>
                    <ForeName>Akihiko</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shimizu</LastName>
                    <ForeName>Wataru</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Aiba</LastName>
                    <ForeName>Takeshi</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Froguel</LastName>
                    <ForeName>Philippe</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Balkau</LastName>
                    <ForeName>Beverley</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lantieri</LastName>
                    <ForeName>Olivier</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Torchio</LastName>
                    <ForeName>Margherita</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wiese</LastName>
                    <ForeName>Cornelia</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weber</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wolswinkel</LastName>
                    <ForeName>Rianne</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Coronel</LastName>
                    <ForeName>Ruben</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boukens</LastName>
                    <ForeName>Bas J</ForeName>
                    <Initials>BJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>B√©zieau</LastName>
                    <ForeName>St√©phane</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Charpentier</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chatel</LastName>
                    <ForeName>St√©phanie</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Despres</LastName>
                    <ForeName>Aurore</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gros</LastName>
                    <ForeName>Fran√ßoise</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kyndt</LastName>
                    <ForeName>Florence</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lecointe</LastName>
                    <ForeName>Simon</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lindenbaum</LastName>
                    <ForeName>Pierre</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Portero</LastName>
                    <ForeName>Vincent</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Violleau</LastName>
                    <ForeName>Jade</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gessler</LastName>
                    <ForeName>Manfred</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tan</LastName>
                    <ForeName>Hanno L</ForeName>
                    <Initials>HL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roden</LastName>
                    <ForeName>Dan M</ForeName>
                    <Initials>DM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Christoffels</LastName>
                    <ForeName>Vincent M</ForeName>
                    <Initials>VM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Le Marec</LastName>
                    <ForeName>Herv√©</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilde</LastName>
                    <ForeName>Arthur A</ForeName>
                    <Initials>AA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Probst</LastName>
                    <ForeName>Vincent</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schott</LastName>
                    <ForeName>Jean-Jacques</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dina</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                    <Identifier Source="ORCID">0000000277227348</Identifier>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Redon</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                    <Identifier Source="ORCID">0000000177512280</Identifier>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>G1002084</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL047678</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL049989</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U19 HL065962</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>07</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051792">Basic Helix-Loop-Helix Transcription Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C405693">HEY2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D062554">NAV1.5 Voltage-Gated Sodium Channel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D062559">NAV1.8 Voltage-Gated Sodium Channel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C568317">SCN10A protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C568320">SCN5A protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015222">Sodium Channels</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2010 Sep 1;26(17):2190-1</RefSource>
                <PMID Version="1">20616382</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Cardiol. 2010 Dec 15;106(12):1758-62</RefSource>
                <PMID Version="1">21126620</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2010 Oct 1;19(19):3885-94</RefSource>
                <PMID Version="1">20639392</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Mar;44(3):323-7</RefSource>
                <PMID Version="1">22327514</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Mol Cell Cardiol. 2012 Mar;52(3):620-9</RefSource>
                <PMID Version="1">22248531</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Dec;42(12):1068-76</RefSource>
                <PMID Version="1">21076409</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2004 Nov;36(11):1181-8</RefSource>
                <PMID Version="1">15502828</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2011 Mar 29;123(12):1270-9</RefSource>
                <PMID Version="1">21403098</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Methods. 2012 Feb;9(2):179-81</RefSource>
                <PMID Version="1">22138821</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Mol Cell Cardiol. 2010 Oct;49(4):543-53</RefSource>
                <PMID Version="1">20659475</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1996 Jan 18;379(6562):257-62</RefSource>
                <PMID Version="1">8538791</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Rev Epidemiol Sante Publique. 1996 Aug;44(4):373-5</RefSource>
                <PMID Version="1">8927780</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1998 Mar 19;392(6673):293-6</RefSource>
                <PMID Version="1">9521325</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mech Dev. 1999 Jul;85(1-2):173-7</RefSource>
                <PMID Version="1">10415358</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2005 Feb 8;111(5):659-70</RefSource>
                <PMID Version="1">15655131</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 2005 Oct;25(20):8960-70</RefSource>
                <PMID Version="1">16199874</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2006 Jun;38(6):644-51</RefSource>
                <PMID Version="1">16648850</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2006 Dec 12;114(24):2584-94</RefSource>
                <PMID Version="1">17145985</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2007 Feb 22;445(7130):881-5</RefSource>
                <PMID Version="1">17293876</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ Res. 2007 Mar 30;100(6):850-5</RefSource>
                <PMID Version="1">17332425</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2007 May 8;104(19):7975-80</RefSource>
                <PMID Version="1">17468400</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2007 Jul;39(7):906-13</RefSource>
                <PMID Version="1">17572673</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2007 Sep;81(3):559-75</RefSource>
                <PMID Version="1">17701901</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Bone Miner Metab. 2008;26(4):373-8</RefSource>
                <PMID Version="1">18600404</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2009 Feb;41(2):157-9</RefSource>
                <PMID Version="1">19151714</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2009 Apr;41(4):399-406</RefSource>
                <PMID Version="1">19305408</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2009 Apr;41(4):407-14</RefSource>
                <PMID Version="1">19305409</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Basic Res Cardiol. 2009 Sep;104(5):511-22</RefSource>
                <PMID Version="1">19255801</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2009 Oct 8;461(7265):747-53</RefSource>
                <PMID Version="1">19812666</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ Cardiovasc Genet. 2009 Aug;2(4):322-8</RefSource>
                <PMID Version="1">20031603</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ Cardiovasc Genet. 2009 Dec;2(6):552-7</RefSource>
                <PMID Version="1">20031634</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Feb;42(2):153-9</RefSource>
                <PMID Version="1">20062060</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Feb;42(2):149-52</RefSource>
                <PMID Version="1">20062061</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Feb;42(2):117-22</RefSource>
                <PMID Version="1">20062063</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Heart Rhythm. 2010 Jan;7(1):33-46</RefSource>
                <PMID Version="1">20129283</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2010 Feb;6(2):e1000864</RefSource>
                <PMID Version="1">20195508</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ Arrhythm Electrophysiol. 2010 Apr;3(2):186-94</RefSource>
                <PMID Version="1">20110552</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2012 Jul;122(7):2519-30</RefSource>
                <PMID Version="1">22706305</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2012 Jul;122(7):2509-18</RefSource>
                <PMID Version="1">22728936</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ Res. 2012 Jul 20;111(3):322-32</RefSource>
                <PMID Version="1">22723299</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ Res. 2012 Jul 20;111(3):333-43</RefSource>
                <PMID Version="1">22723301</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Aug;44(8):848-51</RefSource>
                <PMID Version="1">22820511</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Coll Cardiol. 2012 Oct 9;60(15):1410-8</RefSource>
                <PMID Version="1">22840528</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Coll Cardiol. 1992 Nov 15;20(6):1391-6</RefSource>
                <PMID Version="1">1309182</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2000 Nov 14;102(20):2509-15</RefSource>
                <PMID Version="1">11076825</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 2002 May;22(10):3358-72</RefSource>
                <PMID Version="1">11971969</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Stat Med. 2002 Jun 15;21(11):1539-58</RefSource>
                <PMID Version="1">12111919</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Biol. 2002 Sep 17;12(18):1601-4</RefSource>
                <PMID Version="1">12372253</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16197-202</RefSource>
                <PMID Version="1">12454287</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ital Heart J Suppl. 2002 Oct;3(10):1051-65</RefSource>
                <PMID Version="1">12478833</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Trends Cardiovasc Med. 2003 Aug;13(6):221-6</RefSource>
                <PMID Version="1">12922017</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mutat. 2003 Jun;21(6):651-2</RefSource>
                <PMID Version="1">14961552</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Epidemiol. 2004 Jan;57(1):98-102</RefSource>
                <PMID Version="1">15019016</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ Res. 2004 Sep 3;95(5):540-7</RefSource>
                <PMID Version="1">15297376</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="ErratumIn">
                <RefSource>Nat Genet. 2013 Nov;45(11):1409</RefSource>
                <Note>Borggrefe, Martin [added]; Schimpf, Rainer [added]</Note>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000483">Alleles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051792">Basic Helix-Loop-Helix Transcription Factors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053840">Brugada Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002893">Chromosomes, Human, Pair 3</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002896">Chromosomes, Human, Pair 6</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016757">Death, Sudden, Cardiac</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D014644">Genetic Variation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055106">Genome-Wide Association Study</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D062554">NAV1.5 Voltage-Gated Sodium Channel</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D062559">NAV1.8 Voltage-Gated Sodium Channel</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016017">Odds Ratio</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012097">Repressor Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015222">Sodium Channels</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS528125</OtherID>
        <OtherID Source="NLM">PMC3869788</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2712</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2712</ArticleId>
            <ArticleId IdType="pubmed">23872634</ArticleId>
            <ArticleId IdType="pmc">PMC3869788</ArticleId>
            <ArticleId IdType="mid">NIHMS528125</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8175247</PMID>
        <DateCreated>
            <Year>1994</Year>
            <Month>06</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1994</Year>
            <Month>06</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0091-2174</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>23</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1993</Year>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of psychiatry in medicine</Title>
                <ISOAbbreviation>Int J Psychiatry Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Chloroquine induced mania.</ArticleTitle>
            <Pagination>
                <MedlinePgn>349-56</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To find out whether chloroquine by itself can induce a manic syndrome and to study the course of illness in such cases.</AbstractText>
                <AbstractText Label="METHOD" NlmCategory="METHODS">All cases of manic episodes occurring in clear consciousness were scrutinized and those occurring after the use of chloroquine were included in the study. One case seen by one of the authors in the community was included. The cases were followed for variable periods.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Six cases of chloroquine induced mania were identified of which two subtypes could be delineated with heterogeneous course, variable severity and difference in susceptibility of recurrence with rechallenge.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">It is concluded that chloroquine can cause secondary mania and it should be used cautiously in the predisposed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Akhtar</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Central Institute of Psychiatry, Ranchi, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mukherjee</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Int J Psychiatry Med</MedlineTA>
            <NlmUniqueID>0365646</NlmUniqueID>
            <ISSNLinking>0091-2174</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>886U3H6UFF</RegistryNumber>
                <NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002738">Chloroquine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004565">Electroconvulsive Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008288">Malaria</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011605">Psychoses, Substance-Induced</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011619">Psychotropic Drugs</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1993</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1993</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1993</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8175247</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3991404</PMID>
        <DateCreated>
            <Year>1985</Year>
            <Month>05</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1985</Year>
            <Month>05</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0032-5473</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>61</Volume>
                    <Issue>711</Issue>
                    <PubDate>
                        <Year>1985</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Postgraduate medical journal</Title>
                <ISOAbbreviation>Postgrad Med J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Symptomatic hypercalcaemia precipitated by magnesium therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>47-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A patient with Crohn's disease receiving vitamin D and calcium had normal serum calcium levels when serum magnesium was low. Hypercalcaemia was precipitated when supplemental magnesium was given. The reason why serum calcium was initially normal is probably related to the effect of magnesium deficiency in reducing serum calcium level.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nanji</LastName>
                    <ForeName>A A</ForeName>
                    <Initials>AA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Postgrad Med J</MedlineTA>
            <NlmUniqueID>0234135</NlmUniqueID>
            <ISSNLinking>0032-5473</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>1406-16-2</RegistryNumber>
                <NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7487-88-9</RegistryNumber>
                <NameOfSubstance UI="D008278">Magnesium Sulfate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I38ZP9992A</RegistryNumber>
                <NameOfSubstance UI="D008274">Magnesium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Surg Clin North Am. 1973 Feb;53(1):221-30</RefSource>
                <PMID Version="1">4702999</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Med. 1981;32:245-59</RefSource>
                <PMID Version="1">7013665</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003424">Crohn Disease</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006934">Hypercalcemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008274">Magnesium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008278">Magnesium Sulfate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014807">Vitamin D</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC2418134</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1985</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1985</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1985</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3991404</ArticleId>
            <ArticleId IdType="pmc">PMC2418134</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23607986</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>05</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>10</Month>
            <Day>18</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0333</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>270</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Jul</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology and applied pharmacology</Title>
                <ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>An integrated approach for prospectively investigating a mode-of-action for rodent liver effects.</ArticleTitle>
            <Pagination>
                <MedlinePgn>164-73</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.taap.2013.04.009</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0041-008X(13)00156-7</ELocationID>
            <Abstract>
                <AbstractText>Registration of new plant protection products (e.g., herbicide, insecticide, or fungicide) requires comprehensive mammalian toxicity evaluation including carcinogenicity studies in two species. The outcome of the carcinogenicity testing has a significant bearing on the overall human health risk assessment of the substance and, consequently, approved uses for different crops across geographies. In order to understand the relevance of a specific tumor finding to human health, a systematic, transparent, and hypothesis-driven mode of action (MoA) investigation is, appropriately, an expectation by the regulatory agencies. Here, we describe a novel approach of prospectively generating the MoA data by implementing additional end points to the standard guideline toxicity studies with sulfoxaflor, a molecule in development. This proactive MoA approach results in a more robust integration of molecular with apical end points while minimizing animal use. Sulfoxaflor, a molecule targeting sap-feeding insects, induced liver effects (increased liver weight due to hepatocellular hypertrophy) in an initial palatability probe study for selecting doses for subsequent repeat-dose dietary studies. This finding triggered the inclusion of dose-response investigations of the potential key events for rodent liver carcinogenesis, concurrent with the hazard assessment studies. As predicted, sulfoxaflor induced liver tumors in rats and mice in the bioassays. The MoA data available by the time of the carcinogenicity finding supported the conclusion that the carcinogenic potential of sulfoxaflor was due to CAR/PXR nuclear receptor activation with subsequent hepatocellular proliferation. This MoA was not considered to be relevant to humans as sulfoxaflor is unlikely to induce hepatocellular proliferation in humans and therefore would not be a human liver carcinogen.</AbstractText>
                <CopyrightInformation>Copyright ¬© 2013. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>LeBaron</LastName>
                    <ForeName>Matthew J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Toxicology and Environmental Research &amp; Consulting, The Dow Chemical Company, Midland, MI 48674, USA. MJLeBaron@dow.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Geter</LastName>
                    <ForeName>David R</ForeName>
                    <Initials>DR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rasoulpour</LastName>
                    <ForeName>Reza J</ForeName>
                    <Initials>RJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gollapudi</LastName>
                    <ForeName>B Bhaskar</ForeName>
                    <Initials>BB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thomas</LastName>
                    <ForeName>Johnson</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Murray</LastName>
                    <ForeName>Jennifer</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kan</LastName>
                    <ForeName>H Lynn</ForeName>
                    <Initials>HL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wood</LastName>
                    <ForeName>Amanda J</ForeName>
                    <Initials>AJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elcombe</LastName>
                    <ForeName>Cliff</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vardy</LastName>
                    <ForeName>Audrey</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McEwan</LastName>
                    <ForeName>Jillian</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Terry</LastName>
                    <ForeName>Claire</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Billington</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>04</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
            <NlmUniqueID>0416575</NlmUniqueID>
            <ISSNLinking>0041-008X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007306">Insecticides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013457">Sulfur Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C560328">sulfoxaflor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>63231-63-0</RegistryNumber>
                <NameOfSubstance UI="D012313">RNA</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D019363">Cytochrome P-450 CYP1A1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D019362">Cytochrome P-450 CYP2B1</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019363">Cytochrome P-450 CYP1A1</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019362">Cytochrome P-450 CYP2B1</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007306">Insecticides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008810">Mice, Inbred C57BL</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008813">Mice, Inbred ICR</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008862">Microsomes, Liver</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011725">Pyridines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012313">RNA</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011916">Rats, Inbred F344</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D060888">Real-Time Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013457">Sulfur Compounds</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018675">Toxicity Tests</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0041-008X(13)00156-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.taap.2013.04.009</ArticleId>
            <ArticleId IdType="pubmed">23607986</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2364259</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>08</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>08</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0007-1935</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>146</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <MedlineDate>1990 May-Jun</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>The British veterinary journal</Title>
                <ISOAbbreviation>Br. Vet. J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of repeated topical application of dichlorvos on blood enzymes and its toxicity in buffalo calves (Bubalus bubalis).</ArticleTitle>
            <Pagination>
                <MedlinePgn>264-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Dichlorvos was applied as spray at 1 and 2% concentrations daily for a period of 28 and 21 consecutive days, respectively to buffalo calves. Animals sprayed with 1% dichlorvos displayed mild to moderate clinical signs of toxicosis during the 4th week of exposure. The higher concentration (2%) produced clinical signs of poisoning after 12-16 applications, and was lethal to one of three animals. Daily spraying of dichlorvos at both concentrations inactivated erythrocyte cholinesterase (ChE) (15-21%), plasma ChE (17-20%) and serum carboxylesterase (5-10%) within 3 days. The extent of inhibition of esterases was increased with repeated treatment and maximal inhibition of erythrocyte ChE (80-89%), plasma ChE (81-91%) and serum carboxylesterase (33-54%) with 1 and 2% concentrations was observed on the 28th and 21st day after start of application, respectively. In surviving animals, blood esterases remained inactivated to the extent of 14-65% on the 14th day after the termination of treatment. Dichlorvos at both concentrations significantly (P less than 0.01) elevated the serum levels of aspartate aminotransferase, alanine aminotransferase, acid phosphatase and alkaline phosphatase. The activities of these enzymes in surviving animals recovered to control values within 14 days after the final application of dichlorvos.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Raina</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology, College of Veterinary Science, Punjab Agricultural University, Ludhiana, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Srivastava</LastName>
                    <ForeName>A K</ForeName>
                    <Initials>AK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malik</LastName>
                    <ForeName>J K</ForeName>
                    <Initials>JK</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Br Vet J</MedlineTA>
            <NlmUniqueID>0372554</NlmUniqueID>
            <ISSNLinking>0007-1935</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000336">Aerosols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004798">Enzymes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7U370BPS14</RegistryNumber>
                <NameOfSubstance UI="D004006">Dichlorvos</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000287">Administration, Topical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000336">Aerosols</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002020">Buffaloes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004006">Dichlorvos</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004798">Enzymes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1990</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1990</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1990</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2364259</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12086152</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>06</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>01</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2012</Year>
            <Month>06</Month>
            <Day>05</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0040-8727</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>196</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Tohoku journal of experimental medicine</Title>
                <ISOAbbreviation>Tohoku J. Exp. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Congenital central hypoventilation syndrome: a novel mutation of the RET gene in an isolated case.</ArticleTitle>
            <Pagination>
                <MedlinePgn>241-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Recently, a few genetic abnormalities were identified in congenital central hypoventilation syndrome (CCHS or Ondine's curse). CCHS is often associated with other neurocristopathies, especially with Hirschsprung's disease (HSCR). Mutations of the genes involved in the receptor tyrosine kinase RET (REarranged during Transfection) (RET)-glial cell line-derived neurotrophic factor (GDNF) and/or endothelin 3 (EDN3)-endothelin receptor-B (EDNRB) signaling pathway have been found in some of HSCR patients. In this study, we analyzed candidates for HSCR, namely the RET, GDNF, EDN3 and EDNRB genes in three isolated CCHS patients to confirm the hypothesis that some CCHS patients have a common genetic abnormality with patients having HSCR or other neurocristopathies. We found a novel R114H mutation of the RET gene in one patient. The R114H mutation is unlikely to be a polymorphism and appears to be associated with CCHS. In addition, we also examined the HOX11L2 (RNX) gene, for which knock-out mice showed CCHS-like syndrome in these isolated CCHS patients and did not detected any mutation. Further cases should be analyzed for more candidates to clarify the pathophysiology of CCHS.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kanai</LastName>
                    <ForeName>Masayo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Yamagata University School of Medicine, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Numakura</LastName>
                    <ForeName>Chikahiko</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sasaki</LastName>
                    <ForeName>Ayako</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shirahata</LastName>
                    <ForeName>Emi</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akaba</LastName>
                    <ForeName>Kazuhiro</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hashimoto</LastName>
                    <ForeName>Motoya</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hasegawa</LastName>
                    <ForeName>Hisaya</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shirasawa</LastName>
                    <ForeName>Senji</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hayasaka</LastName>
                    <ForeName>Kiyoshi</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Tohoku J Exp Med</MedlineTA>
            <NlmUniqueID>0417355</NlmUniqueID>
            <ISSNLinking>0040-8727</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019334">Endothelin-3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C495039">GDNF protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C495040">Gdnf protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051100">Glial Cell Line-Derived Neurotrophic Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051097">Glial Cell Line-Derived Neurotrophic Factor Receptors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015513">Oncogene Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D044023">Receptor, Endothelin B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017466">Receptors, Endothelin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C489494">TLX3 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C487378">Tlx1 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>143275-75-6</RegistryNumber>
                <NameOfSubstance UI="C071250">TLX1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D051096">Proto-Oncogene Proteins c-ret</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D020794">Receptor Protein-Tyrosine Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C416649">Ret oncogene protein, Drosophila</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C494999">Ret protein, mouse</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D029721">Drosophila Proteins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019334">Endothelin-3</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051100">Glial Cell Line-Derived Neurotrophic Factor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051097">Glial Cell Line-Derived Neurotrophic Factor Receptors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006627">Hirschsprung Disease</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018398">Homeodomain Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009414">Nerve Growth Factors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015513">Oncogene Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010375">Pedigree</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011518">Proto-Oncogene Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051096">Proto-Oncogene Proteins c-ret</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020794">Receptor Protein-Tyrosine Kinases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D044023">Receptor, Endothelin B</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017466">Receptors, Endothelin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020182">Sleep Apnea, Central</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>6</Month>
                <Day>28</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>1</Month>
                <Day>8</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>6</Month>
                <Day>28</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12086152</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11451783</PMID>
        <DateCreated>
            <Year>2001</Year>
            <Month>07</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2001</Year>
            <Month>08</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0959-8138</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>323</Volume>
                    <Issue>7304</Issue>
                    <PubDate>
                        <Year>2001</Year>
                        <Month>Jul</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMJ (Clinical research ed.)</Title>
                <ISOAbbreviation>BMJ</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Drug points: Neonatal convulsions after withdrawal of baclofen.</ArticleTitle>
            <Pagination>
                <MedlinePgn>85</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ratnayaka</LastName>
                    <ForeName>B D</ForeName>
                    <Initials>BD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neonatal Medicine, City Hospital, Nottingham NG5 1PB.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dhaliwal</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Watkin</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMJ</MedlineTA>
            <NlmUniqueID>8900488</NlmUniqueID>
            <ISSNLinking>0959-535X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018755">GABA Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009125">Muscle Relaxants, Central</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>H789N3FKE8</RegistryNumber>
                <NameOfSubstance UI="D001418">Baclofen</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Postgrad Med J. 1980 Feb;56(652):108-9</RefSource>
                <PMID Version="1">6771749</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Neurol. 1981 Sep;38(9):588-9</RefSource>
                <PMID Version="1">6791618</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1982 Sep 4;2(8297):556-7</RefSource>
                <PMID Version="1">6125710</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Med Assoc. 1984 May;76(5):533, 537-8</RefSource>
                <PMID Version="1">6737510</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurology. 1992 Mar;42(3 Pt 1):697-8</RefSource>
                <PMID Version="1">1549245</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001418">Baclofen</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018755">GABA Agonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008431">Maternal-Fetal Exchange</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009125">Muscle Relaxants, Central</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009357">Neonatal Abstinence Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010264">Paraplegia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011248">Pregnancy Complications</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC34543</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2001</Year>
                <Month>7</Month>
                <Day>14</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>8</Month>
                <Day>17</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2001</Year>
                <Month>7</Month>
                <Day>14</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11451783</ArticleId>
            <ArticleId IdType="pmc">PMC34543</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">22932130</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>10</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1473-5741</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>23</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anti-cancer drugs</Title>
                <ISOAbbreviation>Anticancer Drugs</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Targeted therapy for lung cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1016-21</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Lung cancer is considered the number one killer among all cancers. Recent observations have altered the treatment paradigm for non-small-cell lung cancer (NSCLC). The discovery of activating mutations in the epidermal growth factor receptor and anaplastic lymphoma kinase positivity has made personalized treatment for NSCLC more feasible. Both erlotinib and crizotinib have been shown to be effective and safe for subgroup populations, and now personalized treatment for nonsquamous NSCLC has progressed even further. New tyrosine kinase inhibitors are being tested, resistant mutations are being studied, and new detection systems are being incorporated; all these developments will make the detection and treatment of the deadliest cancer more affordable, practical, and effective. The National Comprehensive Cancer Network has already incorporated these new developments into their guidelines for advanced nonsquamous NSCLC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Petrosyan</LastName>
                    <ForeName>Frunze</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fairview Hospital, A Cleveland Clinic Hospital, Cleveland, Ohio, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Daw</LastName>
                    <ForeName>Hamed</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haddad</LastName>
                    <ForeName>Abdo</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spiro</LastName>
                    <ForeName>Timothy</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Anticancer Drugs</MedlineTA>
            <NlmUniqueID>9100823</NlmUniqueID>
            <ISSNLinking>0959-4973</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>53AH36668S</RegistryNumber>
                <NameOfSubstance UI="C551994">crizotinib</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J4T82NDH7E</RegistryNumber>
                <NameOfSubstance UI="C400278">erlotinib</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002289">Carcinoma, Non-Small-Cell Lung</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D058990">Molecular Targeted Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D047428">Protein Kinase Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011720">Pyrazoles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011725">Pyridines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011799">Quinazolines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>8</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>8</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CAD.0b013e3283585149</ArticleId>
            <ArticleId IdType="pubmed">22932130</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1727206</PMID>
        <DateCreated>
            <Year>1992</Year>
            <Month>01</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1992</Year>
            <Month>01</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0098-1532</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>20</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1992</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Medical and pediatric oncology</Title>
                <ISOAbbreviation>Med. Pediatr. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Behavioral effects of corticosteroids in children with acute lymphoblastic leukemia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>13-21</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We evaluated the behavior of 38 children with standard-risk and high-risk acute lymphoblastic leukemia who received corticosteroids as part of their antileukemia chemotherapy. Each patient was assessed on two occasions: 16 weeks following remission and 1 year thereafter. Parent reports on emotional lability, attention span/hyperactivity, sleep disturbance, listlessness, peer relations, and depressed mood were obtained for 4 consecutive weeks: week before, week during, and 2 weeks after treatment administration. At the 16 week evaluation, standard-risk (N = 17) and high-risk (N = 21) treatment differed by steroid dose and systemic chemotherapy, while at the 1 year testing, treatment differed only by steroid dose (prednisone 40 mg/m2 vs. 120 mg/m2). Statistically significant changes in all measures were observed during treatment as compared with before and after treatment for both risk groups and assessment times. High-risk patients exhibited greater behavioral effects than standard-risk patients only for emotional lability, listlessness, and depressed mood at the 16 week testing, when both steroid dose and chemotherapy differed. Girls had slightly greater behavioral effects than boys, while no influence of age was observed. At the doses tested, steroid dose per se does not appear to be the primary variable affecting behavioral changes.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Drigan</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Dana Farber Cancer Institute, Boston, MA 02115.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spirito</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gelber</LastName>
                    <ForeName>R D</ForeName>
                    <Initials>RD</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Med Pediatr Oncol</MedlineTA>
            <NlmUniqueID>7506654</NlmUniqueID>
            <ISSNLinking>0098-1532</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>04079A1RDZ</RegistryNumber>
                <NameOfSubstance UI="D003561">Cytarabine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>57-22-7</RegistryNumber>
                <NameOfSubstance UI="D014750">Vincristine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>80168379AG</RegistryNumber>
                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>E7WED276I5</RegistryNumber>
                <NameOfSubstance UI="D015122">6-Mercaptopurine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>VB0R961HZT</RegistryNumber>
                <NameOfSubstance UI="D011241">Prednisone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YL5FZ2Y5U1</RegistryNumber>
                <NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015122">6-Mercaptopurine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001288">Attention</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002652">Child Behavior</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003561">Cytarabine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003863">Depression</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004317">Doxorubicin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004347">Drug Interactions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004644">Emotions</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007398">Interpersonal Relations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008727">Methotrexate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D054198">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011241">Prednisone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012737">Sex Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012890">Sleep</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1727206</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23123254</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>04</Month>
            <Day>05</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>05</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7786</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>203</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Mar</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chemico-biological interactions</Title>
                <ISOAbbreviation>Chem. Biol. Interact.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Assessing protection against OP pesticides and nerve agents provided by wild-type HuPON1 purified from Trichoplusia ni larvae or induced via adenoviral infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>177-80</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cbi.2012.10.015</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0009-2797(12)00221-9</ELocationID>
            <Abstract>
                <AbstractText>Human paraoxonase-1 (HuPON1) has been proposed as a catalytic bioscavenger of organophosphorus (OP) pesticides and nerve agents. We assessed the potential of this enzyme to protect against OP poisoning using two different paradigms. First, recombinant HuPON1 purified from cabbage loopers (iPON1; Trichoplusia ni) was administered to guinea pigs, followed by exposure to at least 2 times the median lethal dose (LD(50)) of the OP nerve agents tabun (GA), sarin (GB), soman (GD), and cyclosarin (GF), or chlorpyrifos oxon, the toxic metabolite of the OP pesticide chlorpyrifos. In the second model, mice were infected with an adenovirus that induced expression of HuPON1 and then exposed to sequential doses of GD, VX, or (as reported previously) diazoxon, the toxic metabolite of the OP pesticide diazinon. In both animal models, the exogenously added HuPON1 protected animals against otherwise lethal doses of the OP pesticides but not against the nerve agents. Together, the results support prior modeling and in vitro activity data which suggest that wild-type HuPON1 does not have sufficient catalytic activity to provide in vivo protection against nerve agents.</AbstractText>
                <CopyrightInformation>Published by Elsevier Ireland Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hodgins</LastName>
                    <ForeName>Sean M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Physiology and Immunology Branch, Research Division, US Army Medical Research Institute of Chemical Defense, 3100 Ricketts Point Road, Aberdeen Proving Ground, MD 21010-5400, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kasten</LastName>
                    <ForeName>Shane A</ForeName>
                    <Initials>SA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harrison</LastName>
                    <ForeName>Joshua</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Otto</LastName>
                    <ForeName>Tamara C</ForeName>
                    <Initials>TC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oliver</LastName>
                    <ForeName>Zeke P</ForeName>
                    <Initials>ZP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rezk</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reeves</LastName>
                    <ForeName>Tony E</ForeName>
                    <Initials>TE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chilukuri</LastName>
                    <ForeName>Nageswararao</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cerasoli</LastName>
                    <ForeName>Douglas M</ForeName>
                    <Initials>DM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Chem Biol Interact</MedlineTA>
            <NlmUniqueID>0227276</NlmUniqueID>
            <ISSNLinking>0009-2797</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000931">Antidotes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002619">Chemical Warfare Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010755">Organophosphates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009943">Organophosphorus Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010575">Pesticides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5598-15-2</RegistryNumber>
                <NameOfSubstance UI="C009618">O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>77-81-6</RegistryNumber>
                <NameOfSubstance UI="C009374">tabun</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>96-64-0</RegistryNumber>
                <NameOfSubstance UI="D012999">Soman</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>B4XG72QGFM</RegistryNumber>
                <NameOfSubstance UI="D012524">Sarin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.8.1</RegistryNumber>
                <NameOfSubstance UI="D043303">Aryldialkylphosphatase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.8.1</RegistryNumber>
                <NameOfSubstance UI="C468406">PON1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JCS58I644W</RegistryNumber>
                <NameOfSubstance UI="D004390">Chlorpyrifos</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>VM36F9N236</RegistryNumber>
                <NameOfSubstance UI="C053914">cyclohexyl methylphosphonofluoridate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000931">Antidotes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D043303">Aryldialkylphosphatase</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002619">Chemical Warfare Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004390">Chlorpyrifos</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006168">Guinea Pigs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009036">Moths</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010755">Organophosphates</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009943">Organophosphorus Compounds</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010575">Pesticides</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011994">Recombinant Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012524">Sarin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012999">Soman</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>5</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0009-2797(12)00221-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cbi.2012.10.015</ArticleId>
            <ArticleId IdType="pubmed">23123254</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11451787</PMID>
        <DateCreated>
            <Year>2001</Year>
            <Month>07</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2001</Year>
            <Month>08</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0959-8138</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>323</Volume>
                    <Issue>7304</Issue>
                    <PubDate>
                        <Year>2001</Year>
                        <Month>Jul</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMJ (Clinical research ed.)</Title>
                <ISOAbbreviation>BMJ</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Unsuspected nephrogenic diabetes insipidus.</ArticleTitle>
            <Pagination>
                <MedlinePgn>96-7</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Waise</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Endocrine Clinic, Friarage Hospital, Northallerton, North Yorkshire DL6 1JG. awaise@nahs-tr.northy.nhs.uk</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fisken</LastName>
                    <ForeName>R A</ForeName>
                    <Initials>RA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMJ</MedlineTA>
            <NlmUniqueID>8900488</NlmUniqueID>
            <ISSNLinking>0959-535X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2BMD2GNA4V</RegistryNumber>
                <NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Scott Med J. 1997 Feb;42(1):16-7</RefSource>
                <PMID Version="1">9226773</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med. 1975 Aug;59(2):153-7</RefSource>
                <PMID Version="1">168770</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychol Med. 1989 Nov;19(4):825-31</RefSource>
                <PMID Version="1">2687916</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 1977 Apr;86(4):446-7</RefSource>
                <PMID Version="1">848808</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Q J Med. 1984 Summer;53(211):369-79</RefSource>
                <PMID Version="1">6484119</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 1976 Jul;10(1):82-95</RefSource>
                <PMID Version="1">181631</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018692">Antimanic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018500">Diabetes Insipidus, Nephrogenic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006760">Hospitalization</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016651">Lithium Carbonate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014882">Water-Electrolyte Balance</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC1120756</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2001</Year>
                <Month>7</Month>
                <Day>14</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>8</Month>
                <Day>17</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2001</Year>
                <Month>7</Month>
                <Day>14</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11451787</ArticleId>
            <ArticleId IdType="pmc">PMC1120756</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23221805</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>02</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>07</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1460-2083</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>22</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Mar</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Human molecular genetics</Title>
                <ISOAbbreviation>Hum. Mol. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Deficiency of FRAS1-related extracellular matrix 1 (FREM1) causes congenital diaphragmatic hernia in humans and mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1026-38</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/dds507</ELocationID>
            <Abstract>
                <AbstractText>Congenital diaphragmatic hernia (CDH) is a common life-threatening birth defect. Recessive mutations in the FRAS1-related extracellular matrix 1 (FREM1) gene have been shown to cause bifid nose with or without anorectal and renal anomalies (BNAR) syndrome and Manitoba oculotrichoanal (MOTA) syndrome, but have not been previously implicated in the development of CDH. We have identified a female child with an isolated left-sided posterolateral CDH covered by a membranous sac who had no features suggestive of BNAR or MOTA syndromes. This child carries a maternally-inherited ~86 kb FREM1 deletion that affects the expression of FREM1's full-length transcripts and a paternally-inherited splice site mutation that causes activation of a cryptic splice site, leading to a shift in the reading frame and premature termination of all forms of the FREM1 protein. This suggests that recessive FREM1 mutations can cause isolated CDH in humans. Further evidence for the role of FREM1 in the development of CDH comes from an N-ethyl-N-nitrosourea -derived mouse strain, eyes2, which has a homozygous truncating mutation in Frem1. Frem1(eyes2) mice have eye defects, renal agenesis and develop retrosternal diaphragmatic hernias which are covered by a membranous sac. We confirmed that Frem1 is expressed in the anterior portion of the developing diaphragm and found that Frem1(eyes2) embryos had decreased levels of cell proliferation in their developing diaphragms when compared to wild-type embryos. We conclude that FREM1 plays a critical role in the development of the diaphragm and that FREM1 deficiency can cause CDH in both humans and mice.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Beck</LastName>
                    <ForeName>Tyler F</ForeName>
                    <Initials>TF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Veenma</LastName>
                    <ForeName>Danielle</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shchelochkov</LastName>
                    <ForeName>Oleg A</ForeName>
                    <Initials>OA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Zhiyin</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Bum Jun</ForeName>
                    <Initials>BJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zaveri</LastName>
                    <ForeName>Hitisha P</ForeName>
                    <Initials>HP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Bever</LastName>
                    <ForeName>Yolande</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Sunju</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Douben</LastName>
                    <ForeName>Hannie</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bertin</LastName>
                    <ForeName>Terry K</ForeName>
                    <Initials>TK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patel</LastName>
                    <ForeName>Pragna I</ForeName>
                    <Initials>PI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Brendan</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tibboel</LastName>
                    <ForeName>Dick</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Klein</LastName>
                    <ForeName>Annelies</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stockton</LastName>
                    <ForeName>David W</ForeName>
                    <Initials>DW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Justice</LastName>
                    <ForeName>Monica J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scott</LastName>
                    <ForeName>Daryl A</ForeName>
                    <Initials>DA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>5P30 HD024064</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 HD024064</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA115503</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HD06466</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HD064667</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R03 EY014854</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 GM008307</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 HD39372</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Hum Mol Genet</MedlineTA>
            <NlmUniqueID>9208958</NlmUniqueID>
            <ISSNLinking>0964-6906</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016326">Extracellular Matrix Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C475145">FRAS1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C492585">Frem1 protein, mouse</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <SupplMeshList>
            <SupplMeshName Type="Disease" UI="C535441">Bifid nose</SupplMeshName>
        </SupplMeshList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med Genet C Semin Med Genet. 2007 May 15;145C(2):158-71</RefSource>
                <PMID Version="1">17436298</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Pediatr Surg. 2007 May;16(2):88-93</RefSource>
                <PMID Version="1">17462560</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med Genet A. 2007 Sep 15;143A(18):2204-12</RefSource>
                <PMID Version="1">17702015</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Ultrasound Med. 2008 May;27(5):707-13</RefSource>
                <PMID Version="1">18424645</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genet Couns. 2008;19(3):331-9</RefSource>
                <PMID Version="1">18990989</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Med Genet. 2009 Mar-Jun;52(2-3):153-6</RefSource>
                <PMID Version="1">19233321</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med Genet A. 2009 Aug;149A(8):1661-77</RefSource>
                <PMID Version="1">19606479</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Surg Int. 2009 Sep;25(9):733-43</RefSource>
                <PMID Version="1">19669650</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2009 Sep;85(3):414-8</RefSource>
                <PMID Version="1">19732862</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2010 Mar 5;285(10):7222-32</RefSource>
                <PMID Version="1">19940113</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Genet. 2010 Jul;47(7):492-8</RefSource>
                <PMID Version="1">19955558</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Methods Enzymol. 2010;477:297-312</RefSource>
                <PMID Version="1">20699147</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Prenat Diagn. 2010 Dec;30(12-13):1198-206</RefSource>
                <PMID Version="1">21064195</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2011 Jan;39(Database issue):D225-9</RefSource>
                <PMID Version="1">21109532</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2010;5(12):e15348</RefSource>
                <PMID Version="1">21203572</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Genet. 2011 May;48(5):299-307</RefSource>
                <PMID Version="1">21525063</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Genet. 2011 Jun;48(6):375-82</RefSource>
                <PMID Version="1">21507892</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2011 Sep;7(9):e1002278</RefSource>
                <PMID Version="1">21931569</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2012 Apr 6;287(15):12348-52</RefSource>
                <PMID Version="1">22262840</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Genet. 2012 May;49(5):303-6</RefSource>
                <PMID Version="1">22510445</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Vis. 2012;18:1301-11</RefSource>
                <PMID Version="1">22690109</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2012 Sep 15;21(18):4115-25</RefSource>
                <PMID Version="1">22723016</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genet Couns. 2001;12(1):101-2</RefSource>
                <PMID Version="1">11332973</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Dysmorphol. 2002 Jan;11(1):33-8</RefSource>
                <PMID Version="1">11822703</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5217-22</RefSource>
                <PMID Version="1">12702769</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2003 Jun;34(2):203-8</RefSource>
                <PMID Version="1">12766769</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mech Dev. 2003 Sep;120(9):1059-70</RefSource>
                <PMID Version="1">14550534</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2004 Sep;75(3):475-84</RefSource>
                <PMID Version="1">15258860</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13560-5</RefSource>
                <PMID Version="1">15345741</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Hered. 1981 Jul-Aug;72(4):293</RefSource>
                <PMID Version="1">6793660</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Genet. 1988 Jul;25(7):480-7</RefSource>
                <PMID Version="1">3050095</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Genet. 1990 Jun;37(6):494-5</RefSource>
                <PMID Version="1">2166630</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Pediatr. 1991 Aug;150(10):726-9</RefSource>
                <PMID Version="1">1915486</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med Genet. 1992 Apr 1;42(6):793-9</RefSource>
                <PMID Version="1">1554017</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Histol Histopathol. 1992 Apr;7(2):231-6</RefSource>
                <PMID Version="1">1515706</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fetal Diagn Ther. 1995 Jan-Feb;10(1):52-9</RefSource>
                <PMID Version="1">7710680</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Perinatol. 1996 Dec;23(4):671-88</RefSource>
                <PMID Version="1">8982563</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Perinatol. 1996 Dec;23(4):689-99</RefSource>
                <PMID Version="1">8982564</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pediatr Surg. 1997 Nov;32(11):1634-6</RefSource>
                <PMID Version="1">9396544</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Endocrinol. 2005 Apr;19(4):972-81</RefSource>
                <PMID Version="1">15625238</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2005 May;37(5):520-5</RefSource>
                <PMID Version="1">15838507</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Dyn. 2005 Oct;234(2):371-86</RefSource>
                <PMID Version="1">16123981</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gene Expr Patterns. 2006 Aug;6(6):653-65</RefSource>
                <PMID Version="1">16466971</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):11981-6</RefSource>
                <PMID Version="1">16880404</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Biol. 2007 Jan 15;301(2):602-14</RefSource>
                <PMID Version="1">17069789</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2007 Feb 15;16(4):424-30</RefSource>
                <PMID Version="1">17210672</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Exp Cell Res. 2007 Mar 10;313(5):910-20</RefSource>
                <PMID Version="1">17240369</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med Genet A. 2007 Apr 15;143A(8):853-7</RefSource>
                <PMID Version="1">17352387</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2007 May;80(5):825-45</RefSource>
                <PMID Version="1">17436238</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>IUBMB Life. 2007 Jul;59(7):427-35</RefSource>
                <PMID Version="1">17654118</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003964">Diaphragm</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000254">growth &amp; development</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016326">Extracellular Matrix Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005808">Genes, Recessive</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006548">Hernia, Diaphragmatic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D065630">Hernias, Diaphragmatic, Congenital</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006720">Homozygote</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009666">Nose</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000002">abnormalities</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009668">Nose Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017384">Sequence Deletion</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC3561915</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">dds507</ArticleId>
            <ArticleId IdType="doi">10.1093/hmg/dds507</ArticleId>
            <ArticleId IdType="pubmed">23221805</ArticleId>
            <ArticleId IdType="pmc">PMC3561915</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9293047</PMID>
        <DateCreated>
            <Year>1997</Year>
            <Month>09</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1997</Year>
            <Month>09</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2007</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0965-2140</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>92</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>1997</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Addiction (Abingdon, England)</Title>
                <ISOAbbreviation>Addiction</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nicotine withdrawal in women.</ArticleTitle>
            <Pagination>
                <MedlinePgn>889-902</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Associations between self-report symptom profiles for nicotine withdrawal, personality (TPQ, EPQ-R), life-time history of psychopathology and smoking history were examined in data obtained from 553 female adult Australian twins (246 regular smokers), aged 32-48 years, who had participated in a telephone interview survey that included life-time assessments of smoking history, nicotine dependence and symptoms of withdrawal. Two hundred and two respondents were from high-risk pairs where either the respondent or the respondent's co-twin had reported a life-time history of alcohol dependence; 351 were from control pairs. Latent class analysis was used to identify subtypes ('classes') of smokers reporting similar withdrawal symptom profiles. Three major classes were identified which appeared to represent a continuum from mild to severe nicotine withdrawal. Smokers from the severe withdrawal class were best characterized by hands shaking and by the prominence of depressive features. There were marked increases in life-time alcohol dependence rates as a function of severity class. In contrast, significantly elevated rates of major depression, conduct disorder and anxiety disorder were observed only among smokers from the most severe withdrawal class. Neuroticism was the only personality factor strongly associated with the development of withdrawal symptoms.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Madden</LastName>
                    <ForeName>P A</ForeName>
                    <Initials>PA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bucholz</LastName>
                    <ForeName>K K</ForeName>
                    <Initials>KK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dinwiddie</LastName>
                    <ForeName>S H</ForeName>
                    <Initials>SH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Slutske</LastName>
                    <ForeName>W S</ForeName>
                    <Initials>WS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bierut</LastName>
                    <ForeName>L J</ForeName>
                    <Initials>LJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Statham</LastName>
                    <ForeName>D J</ForeName>
                    <Initials>DJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dunne</LastName>
                    <ForeName>M P</ForeName>
                    <Initials>MP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martin</LastName>
                    <ForeName>N G</ForeName>
                    <Initials>NG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Heath</LastName>
                    <ForeName>A C</ForeName>
                    <Initials>AC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>AA07535</GrantID>
                    <Acronym>AA</Acronym>
                    <Agency>NIAAA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>AA07728</GrantID>
                    <Acronym>AA</Acronym>
                    <Agency>NIAAA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DA00272</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
                <PublicationType UI="D018486">Twin Study</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Addiction</MedlineTA>
            <NlmUniqueID>9304118</NlmUniqueID>
            <ISSNLinking>0965-2140</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>54-11-5</RegistryNumber>
                <NameOfSubstance UI="D009538">Nicotine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D004200">Diseases in Twins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001523">Mental Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009538">Nicotine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010551">Personality</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012907">Smoking</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013375">Substance Withdrawal Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014029">Tobacco Use Disorder</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1997</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1997</Year>
                <Month>9</Month>
                <Day>18</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1997</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9293047</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12811651</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>07</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>04</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2004</Year>
            <Month>11</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0931-041X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>18</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pediatric nephrology (Berlin, Germany)</Title>
                <ISOAbbreviation>Pediatr. Nephrol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Arterial hypertension with brachydactyly in a 15-year-old boy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>814-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Autosomal dominant brachydactyly with hypertension is the only form of monogenic hypertension which is not sodium dependent. The disease is characterized by brachydactyly type E, short stature, arterial hypertension and aberrant loop of posterior inferior cerebellar artery (PICA) causing neurovascular conflict. So far the syndrome was described in one family in Turkey and two in Canada. We report a case of a 15-year-old boy who was admitted because of arterial hypertension 160/100 mmHg. He complained also of attacks of bilateral numbness of hands with deterioration of visual field. Examination revealed short stature (156 cm) and bone deformities of hands and feet consistent with brachydactyly type E. Ophthalmoscopy showed mild narrowing of retinal arteries. Serum electrolytes, blood gases, and renal function were normal. Renin activity and aldosterone concentrations were raised, and 24-h urinary excretion of catecholamines and urinary steroid profile were in normal range. Renal Doppler ultrasound was normal, but renal scintigraphy suggested vascular changes in the left kidney. Echocardiographic examination, besides mild left ventricular hypertrophy, was normal. Magnetic resonance angiography (angio-MR) revealed bilateral abnormal PICA loops and neurovascular conflict. Spiral angiotomography of renal arteries revealed narrow additional left renal artery. Both nonconsanguineous parents and younger brother were healthy, with normal height, without bone deformities, and had normal intracranial vessels. Amlodipine and metoprolol were given, and blood pressure lowered to 143/87. Adding rilmenidine gave no effect and enalapril was then added. It led to further improvement in blood pressure control. To our knowledge, this is the first pediatric description of a sporadic form of autosomal dominant brachydactyly with hypertension with abnormalities of brain and renal arteries.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Litwin</LastName>
                    <ForeName>Mieczys≈Çaw</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Nephrology and Kidney Transplantation, The Children's Memorial Health Institute, Al Dzieci Polskich 20, 04-736, Warsaw, Poland. litwin@czd.waw.pl</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jurkiewicz</LastName>
                    <ForeName>Elzbieta</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nowak</LastName>
                    <ForeName>Katarzyna</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ko≈õciesza</LastName>
                    <ForeName>Andrzej</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grenda</LastName>
                    <ForeName>Ryszard</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malczyk</LastName>
                    <ForeName>Katarzyna</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ko≈õciesza</LastName>
                    <ForeName>Iwona</ForeName>
                    <Initials>I</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2003</Year>
                <Month>06</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Pediatr Nephrol</MedlineTA>
            <NlmUniqueID>8708728</NlmUniqueID>
            <ISSNLinking>0931-041X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002536">Cerebral Arteries</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000002">abnormalities</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005799">Genes, Dominant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006228">Hand Deformities, Congenital</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000530">radiography</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006977">Hypertension, Renal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012077">Renal Artery</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000002">abnormalities</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012078">Renal Artery Obstruction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>6</Month>
                <Day>18</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>4</Month>
                <Day>7</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2002</Year>
                <Month>Oct</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2003</Year>
                <Month>Feb</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2003</Year>
                <Month>Mar</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2003</Year>
                <Month>Jun</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>6</Month>
                <Day>18</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12811651</ArticleId>
            <ArticleId IdType="doi">10.1007/s00467-003-1169-2</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">7503798</PMID>
        <DateCreated>
            <Year>1996</Year>
            <Month>01</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1996</Year>
            <Month>01</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0006-2952</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>50</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>1995</Year>
                        <Month>Oct</Month>
                        <Day>26</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical pharmacology</Title>
                <ISOAbbreviation>Biochem. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Naphthylisothiocyanate disposition in bile and its relationship to liver glutathione and toxicity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1469-74</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>1-Naphthylisothiocyanate (ANIT), but not 2-naphthylisothiocyanate (BNIT), produces cholangiolitic hepatitis in rats after a single, oral administration. The mechanisms responsible for the disparate toxic outcomes for these closely related structural isomers are not fully understood. Recent reports suggest that ANIT-induced hepatotoxicity is dependent upon the formation and biliary excretion of a reversible glutathione-ANIT conjugate. To understand better the relationship between hepatic glutathione, secretion into bile and hepatotoxicity, the bile concentrations and hepatotoxicities of ANIT and BNIT were examined in rats with and without pretreatment with buthionine sulfoximine (BSO). ANIT (100 mg/kg, p.o.) caused a 3-fold elevation of plasma alanine aminotransferase activity (ALT), a 6-fold elevation of total plasma bilirubin, and a &gt; 90% reduction in bile flow 24 hr after administration. BNIT, at this same dose and route of administration, did not alter significantly these markers of liver injury. Accumulation of ANIT and BNIT in bile occurred with the same temporal characteristics; however, BNIT accumulated to markedly larger concentrations (292 +/- 83 and 235 +/- 100 microM BNIT and 78 +/- 19 and 29 +/- 13 microM ANIT at 1 and 4 hr, respectively). The accumulation of ANIT and BNIT in bile was coincident with a &gt; 2-fold elevation of reduced glutathione in bile. Pretreatment of rats with BSO decreased hepatic glutathione concentration and reduced the concentration of naphthylisothiocyanates in bile by 85%. Associated with this reduction was an attenuation of ANIT hepatotoxicity. Altogether, these findings indicate that both ANIT and BNIT accumulate in bile in a glutathione-dependent manner, yet they yield different hepatotoxic outcomes. Therefore, the disparity in hepatotoxicities observed with these isomers is not related to a difference in ability to enter bile. Other differences, such as in metabolism, chemical reactivity, conjugate stability and/or cytotoxic potential to bile duct epithelial cells may be more important determinants of hepatotoxicity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jean</LastName>
                    <ForeName>P A</ForeName>
                    <Initials>PA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Toxicology, Michigan State University, East Lansing 48824-1317, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roth</LastName>
                    <ForeName>R A</ForeName>
                    <Initials>RA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>ES04139</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>ES07255</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Biochem Pharmacol</MedlineTA>
            <NlmUniqueID>0101032</NlmUniqueID>
            <ISSNLinking>0006-2952</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>1982-67-8</RegistryNumber>
                <NameOfSubstance UI="D008717">Methionine Sulfoximine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5072-26-4</RegistryNumber>
                <NameOfSubstance UI="D019328">Buthionine Sulfoximine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>551-06-4</RegistryNumber>
                <NameOfSubstance UI="D015058">1-Naphthylisothiocyanate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>GAN16C9B8O</RegistryNumber>
                <NameOfSubstance UI="D005978">Glutathione</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>N2LP7A9XG2</RegistryNumber>
                <NameOfSubstance UI="C031287">2-naphthylisothiocyanate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015058">1-Naphthylisothiocyanate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001646">Bile</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019328">Buthionine Sulfoximine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056486">Drug-Induced Liver Injury</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005978">Glutathione</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007536">Isomerism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008717">Methionine Sulfoximine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1995</Year>
                <Month>10</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1995</Year>
                <Month>10</Month>
                <Day>26</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1995</Year>
                <Month>10</Month>
                <Day>26</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7503798</ArticleId>
            <ArticleId IdType="pii">0006-2952(95)02051-9</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16418614</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>01</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>08</Month>
            <Day>31</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1535-1815</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>22</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pediatric emergency care</Title>
                <ISOAbbreviation>Pediatr Emerg Care</ISOAbbreviation>
            </Journal>
            <ArticleTitle>PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>52-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Palpable purpura is a concerning clinical finding in pediatric patients and can have many causes, including infectious and autoimmune processes. A rare cause, drug-induced vasculitis, may result from the production of antineutrophil cytoplasmic antibodies (ANCAs) in response to a medication. We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions. The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU. Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the vasculitis, a complication described in prior case reports.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hardy</LastName>
                    <ForeName>Olga T</ForeName>
                    <Initials>OT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, Philadelphia, PA 19104-4318, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smolinski</LastName>
                    <ForeName>Kara N</ForeName>
                    <Initials>KN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yan</LastName>
                    <ForeName>Albert C</ForeName>
                    <Initials>AC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grimberg</LastName>
                    <ForeName>Adda</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Pediatr Emerg Care</MedlineTA>
            <NlmUniqueID>8507560</NlmUniqueID>
            <ISSNLinking>0749-5161</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013956">Antithyroid Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>721M9407IY</RegistryNumber>
                <NameOfSubstance UI="D011441">Propylthiouracil</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q51BO43MG4</RegistryNumber>
                <NameOfSubstance UI="D013974">Thyroxine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013956">Antithyroid Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006111">Graves Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011441">Propylthiouracil</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013974">Thyroxine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014424">Turner Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014657">Vasculitis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>1</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>1</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">00006565-200601000-00011</ArticleId>
            <ArticleId IdType="pubmed">16418614</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">14580783</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>10</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>12</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0300-483X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>192</Volume>
                    <Issue>2-3</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Nov</Month>
                        <Day>5</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology</Title>
                <ISOAbbreviation>Toxicology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Impact of dietary exposure to methoxychlor, genistein, or diisononyl phthalate during the perinatal period on the development of the rat endocrine/reproductive systems in later life.</ArticleTitle>
            <Pagination>
                <MedlinePgn>149-70</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>To evaluate the impact of dietary exposure to endocrine disrupting chemicals (EDCs) during the sensitive period of brain sexual differentiation, maternal Sprague-Dawley rats were fed three representative chemicals, methoxychlor (MXC; 24, 240, and 1200 ppm), genistein (GEN; 20, 200, and 1000 ppm), or diisononyl phthalate (DINP; 400, 4000, and 20,000 ppm), from gestational day 15 to postnatal day 10. Soy-free diet was used as a basal diet to eliminate possible estrogenic effects from the standard diet. Offspring were examined in terms of anogenital distances, prepubertal organ weights, onset of puberty, estrous cyclicity, and organ weights and histopathology of endocrine organs at adult stage (week 11) as well as the volumes of sexually dimorphic nucleus of preoptic area (SDN-POA). All chemicals caused signs of maternal toxicity at high doses. MXC, at 1200 ppm, facilitated and delayed the onset of puberty in females and males, respectively, females also showing endocrine disrupting effects thereafter, such as irregular estrous cyclicity and histopathological alterations in the reproductive tract and anterior pituitary. GEN, at all doses, reduced body weight (BW) at week 11, but did not affect endocrine parameters. Treatment with DINP at 20,000 ppm resulted in degeneration of meiotic spermatocytes and Sertoli cells in the testis and decrease of corpora lutea in the ovary at week 11, although changes remained minimal or slight. The SDN-POA volume remained unchanged with all three chemicals. The results demonstrated that perinatal dietary exposure to EDCs for a limited period causes endocrine disruption in offspring only at high doses.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Masutomi</LastName>
                    <ForeName>Naoya</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pathology, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shibutani</LastName>
                    <ForeName>Makoto</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takagi</LastName>
                    <ForeName>Hironori</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Uneyama</LastName>
                    <ForeName>Chikako</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takahashi</LastName>
                    <ForeName>Noriyuki</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hirose</LastName>
                    <ForeName>Masao</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Toxicology</MedlineTA>
            <NlmUniqueID>0361055</NlmUniqueID>
            <ISSNLinking>0300-483X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010795">Phthalic Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4010KIX4CK</RegistryNumber>
                <NameOfSubstance UI="C012125">diisononyl phthalate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>DH2M523P0H</RegistryNumber>
                <NameOfSubstance UI="D019833">Genistein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>RIA79UD69L</RegistryNumber>
                <NameOfSubstance UI="D008731">Methoxychlor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001835">Body Weight</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004703">Endocrine System</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D030762">Estrous Cycle</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019833">Genistein</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008731">Methoxychlor</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009929">Organ Size</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010053">Ovary</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010795">Phthalic Acids</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011297">Prenatal Exposure Delayed Effects</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011301">Preoptic Area</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012098">Reproduction</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012733">Sex Differentiation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013737">Testis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>10</Month>
                <Day>29</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>12</Month>
                <Day>25</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>10</Month>
                <Day>29</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14580783</ArticleId>
            <ArticleId IdType="pii">S0300483X03002695</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2848972</PMID>
        <DateCreated>
            <Year>1989</Year>
            <Month>01</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1989</Year>
            <Month>01</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0085-2538</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>34</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1988</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Kidney international</Title>
                <ISOAbbreviation>Kidney Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria.</ArticleTitle>
            <Pagination>
                <MedlinePgn>494-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A single intravenous injection of puromycin aminonucleoside (PAN) results in marked proteinuria and glomerular morphological changes that are similar to minimal change disease in humans. We examined the effect of hydroxyl radical scavengers and an iron chelator on PAN-induced proteinuria. PAN in a dose of 5 mg/100 g body wt significantly increased urinary protein by day 5 (saline: 15 +/- 2, N = 24: PAN: 63 +/- 17, N = 23, P less than 0.001); the proteinuria rapidly increased thereafter, reaching 216 +/- 34, N = 23 by day 7. Concurrent administration of hydroxyl radical scavengers dimethylthiourea, (DMTU 500 mg/kg followed by 125 mg/kg i.p. twice a day) and sodium benzoate (BENZ, 150 mg/kg followed by 125 mg/kg i.p. twice a day) starting the evening before PAN injection markedly reduced proteinuria throughout the course of the study (urinary protein, mg/24 hours on day 7, mean +/- SEM: PAN: 229 +/- 45, N = 15; PAN + DMTU: 30 +/- 5, N = 18; PAN + BENZ: 80 +/- 18, N = 16. Because of the participation of iron in biological systems to generate hydroxyl radical, we also examined the effect of deferoxamine (DFO, 30 mg/day), an iron chelator, on the PAN-induced proteinuria. Concurrent administration of DFO was also protective. In a second series of experiments, DMTU and DFO (administered as described above and then for two additional days after the PAN) provided marked protection even when they were stopped prior to the onset of proteinuria. The protective effects of two hydroxyl radical scavengers and iron chelator implicate an important role for hydroxyl radical in PAN-induced nephrotic syndrome.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Thakur</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Tulane Medical School, New Orleans, Louisiana.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Walker</LastName>
                    <ForeName>P D</ForeName>
                    <Initials>PD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shah</LastName>
                    <ForeName>S V</ForeName>
                    <Initials>SV</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>AM28452</GrantID>
                    <Acronym>AM</Acronym>
                    <Agency>NIADDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Kidney Int</MedlineTA>
            <NlmUniqueID>0323470</NlmUniqueID>
            <ISSNLinking>0085-2538</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001565">Benzoates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006878">Hydroxides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3352-57-6</RegistryNumber>
                <NameOfSubstance UI="D017665">Hydroxyl Radical</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4A6ZS6Q2CL</RegistryNumber>
                <NameOfSubstance UI="D011691">Puromycin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>58-60-6</RegistryNumber>
                <NameOfSubstance UI="D011692">Puromycin Aminonucleoside</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>61805-96-7</RegistryNumber>
                <NameOfSubstance UI="C038983">1,3-dimethylthiourea</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>65-85-0</RegistryNumber>
                <NameOfSubstance UI="D019817">Benzoic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>GYV9AM2QAG</RegistryNumber>
                <NameOfSubstance UI="D013890">Thiourea</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J06Y7MXW4D</RegistryNumber>
                <NameOfSubstance UI="D003676">Deferoxamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YOW8V9698H</RegistryNumber>
                <NameOfSubstance UI="D004121">Dimethyl Sulfoxide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001565">Benzoates</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019817">Benzoic Acid</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003676">Deferoxamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004121">Dimethyl Sulfoxide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D006878">Hydroxides</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017665">Hydroxyl Radical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011507">Proteinuria</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011691">Puromycin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011692">Puromycin Aminonucleoside</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011919">Rats, Inbred Strains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013890">Thiourea</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1988</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1988</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1988</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2848972</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16600690</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>06</Month>
            <Day>29</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>10</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1525-2167</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology</Title>
                <ISOAbbreviation>Eur J Echocardiogr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hydroxychloroquine-induced restrictive cardiomyopathy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>247-51</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Chloroquine (Hydroxychloroquine)-induced cardiomyopathy is a rare but potentially life-threatening condition. Cessation of the culprit drug, along with aggressive afterload reduction therapy, has been associated with halting of disease progress and even improvement in patients' clinical and histologic status. Echocardiography is a fundamental tool in the identification and assessment of patients with cardiomyopathy, with particular utility in the detailed assessment of biventricular systolic and diastolic function. It also provides an objective and non-invasive means of assessing treatment response. We present a case of a 51-year-old woman with hydroxychloroquine-induced restrictive cardiomyopathy and correlate clinical, echocardiographic and anatomic pathologic findings both at initial presentation and following treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cotroneo</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, The Northern Hospital, Melbourne, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sleik</LastName>
                    <ForeName>Khaled M</ForeName>
                    <Initials>KM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rene Rodriguez</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klein</LastName>
                    <ForeName>Allan L</ForeName>
                    <Initials>AL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2006</Year>
                <Month>04</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Eur J Echocardiogr</MedlineTA>
            <NlmUniqueID>100890618</NlmUniqueID>
            <ISSNLinking>1532-2114</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4QWG6N8QKH</RegistryNumber>
                <NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018501">Antirheumatic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002313">Cardiomyopathy, Restrictive</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006886">Hydroxychloroquine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2005</Year>
                <Month>12</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2006</Year>
                <Month>2</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2006</Year>
                <Month>4</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>17</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1525-2167(06)00032-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.euje.2006.02.002</ArticleId>
            <ArticleId IdType="pubmed">16600690</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3942475</PMID>
        <DateCreated>
            <Year>1986</Year>
            <Month>01</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1986</Year>
            <Month>01</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-990X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>43</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1986</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of general psychiatry</Title>
                <ISOAbbreviation>Arch. Gen. Psychiatry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Maprotiline treatment in depression. A perspective on seizures.</ArticleTitle>
            <Pagination>
                <MedlinePgn>86-90</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Eleven McLean Hospital (Belmont, Mass) depressed patients who experienced seizures while receiving maprotiline hydrochloride are presented, as are data on 87 cases reported to the manufacturer (Ciba-Geigy). Most seizures occurred at high dosages, sometimes after many weeks at a stable dose, but neither rapid dosage escalation nor high drug plasma levels seemed related to seizure occurrence. Our experience suggests that a long-acting metabolite might be responsible for seizures. Ten of the 11 McLean Hospital seizures occurred in patients receiving dosages outside of the since-revised current dosage guidelines, as did 60% of the seizures reported to the company. Data in this study suggest that reductions in maximum dosage of maprotiline prescribed after the initial six weeks of treatment could result in a further decrease in risk of seizures beyond that obtained from previous alterations in regimens.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dessain</LastName>
                    <ForeName>E C</ForeName>
                    <Initials>EC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schatzberg</LastName>
                    <ForeName>A F</ForeName>
                    <Initials>AF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Woods</LastName>
                    <ForeName>B T</ForeName>
                    <Initials>BT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cole</LastName>
                    <ForeName>J O</ForeName>
                    <Initials>JO</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Arch Gen Psychiatry</MedlineTA>
            <NlmUniqueID>0372435</NlmUniqueID>
            <ISSNLinking>0003-990X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000873">Anthracenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2U1W68TROF</RegistryNumber>
                <NameOfSubstance UI="D008376">Maprotiline</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000873">Anthracenes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003866">Depressive Disorder</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008376">Maprotiline</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1986</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1986</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1986</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3942475</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16610002</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>04</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>09</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1007-9327</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>12</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Mar</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>World journal of gastroenterology : WJG</Title>
                <ISOAbbreviation>World J. Gastroenterol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Up-regulation of NAD(P)H quinone oxidoreductase 1 during human liver injury.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1937-40</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To investigate the expression and activity of NAD(P)H quinone oxidoreductase 1 (NQO1) in human liver specimens obtained from patients with liver damage due to acetaminophen (APAP) overdose or primary biliary cirrhosis (PBC).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">NQO1 activity was determined in cytosol from normal, APAP and PBC liver specimens. Western blot and immunohistochemical staining were used to determine patterns of NQO1 expression using a specific antibody against NQO1.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">NQO1 protein was very low in normal human livers. In both APAP and PBC livers, there was strong induction of NQO1 protein levels on Western blot. Correspondingly, significant up-regulation of enzyme activity (16- and 22-fold, P&lt; 0.05) was also observed in APAP and PBC livers, respectively. Immunohistochemical analysis highlighted injury-specific patterns of NQO1 staining in both APAP and PBC livers.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data demonstrate that NQO1 protein and activity are markedly induced in human livers during both APAP overdose and PBC. Up-regulation of this cytoprotective enzyme may represent an adaptive stress response to limit further disease progression by detoxifying reactive species.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Aleksunes</LastName>
                    <ForeName>Lauren M</ForeName>
                    <Initials>LM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, 69 North Eagleville Road, Unit 3092, Storrs, CT 06269-3092, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goedken</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Manautou</LastName>
                    <ForeName>Jos√© E</ForeName>
                    <Initials>JE</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>World J Gastroenterol</MedlineTA>
            <NlmUniqueID>100883448</NlmUniqueID>
            <ISSNLinking>1007-9327</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018712">Analgesics, Non-Narcotic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>362O9ITL9D</RegistryNumber>
                <NameOfSubstance UI="D000082">Acetaminophen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.6.5.2</RegistryNumber>
                <NameOfSubstance UI="D016660">NAD(P)H Dehydrogenase (Quinone)</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.6.5.2</RegistryNumber>
                <NameOfSubstance UI="C447479">NQO1 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 1999 Nov 15;58(10):1547-55</RefSource>
                <PMID Version="1">10535745</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Biol Interact. 2000 Dec 1;129(1-2):77-97</RefSource>
                <PMID Version="1">11154736</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 2001 Feb;59(2):263-8</RefSource>
                <PMID Version="1">11160862</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3410-5</RefSource>
                <PMID Version="1">11248092</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 2002 Feb;61(2):320-5</RefSource>
                <PMID Version="1">11809856</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 2003 Sep 1;374(Pt 2):337-48</RefSource>
                <PMID Version="1">12816537</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Liver Dis. 2003 Aug;23(3):217-26</RefSource>
                <PMID Version="1">14523675</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Oncol. 2004 Mar;24(3):565-74</RefSource>
                <PMID Version="1">14767541</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 2004 May;65(5):1238-47</RefSource>
                <PMID Version="1">15102952</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2004 Jun;79(2):411-22</RefSource>
                <PMID Version="1">15056800</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1980 Sep;77(9):5216-20</RefSource>
                <PMID Version="1">6933553</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 1987 Aug 1;36(15):2473-9</RefSource>
                <PMID Version="1">2440444</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1991 Jun 1;109(1):17-28</RefSource>
                <PMID Version="1">2038746</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1991 Jun 1;109(1):29-40</RefSource>
                <PMID Version="1">2038747</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 1991 Aug 8;42(5):1021-7</RefSource>
                <PMID Version="1">1651729</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 1997 Aug;52(2):300-5</RefSource>
                <PMID Version="1">9271353</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1998 Mar 27;273(13):7382-9</RefSource>
                <PMID Version="1">9516435</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Rev. 2004 Oct;36(3-4):639-54</RefSource>
                <PMID Version="1">15554240</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2005 Jan;83(1):44-52</RefSource>
                <PMID Version="1">15496496</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Free Radic Biol Med. 2000 Aug;29(3-4):246-53</RefSource>
                <PMID Version="1">11035253</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000082">Acetaminophen</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018712">Analgesics, Non-Narcotic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015971">Gene Expression Regulation, Enzymologic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008105">Liver Cirrhosis, Biliary</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008107">Liver Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016660">NAD(P)H Dehydrogenase (Quinone)</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015854">Up-Regulation</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC4087521</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>4</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>9</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>4</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16610002</ArticleId>
            <ArticleId IdType="pmc">PMC4087521</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
